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high-resolution crystal structure of the B2-tubulin complex was obtained, shedding light 
on future design of new (+)-discodermolide analogs based on a better understanding of 
binding mechanism at molecular level.  
Chapter two describes a “high-risk” synthetic study towards the natural product (–)-
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CHAPTER 1. DESIGN, SYNTHESIS AND BIOLOGICAL EVALUATION OF (+)-
DISCODERMOLIDE ANALOGS 
 
1.1 Introduction 
1.1.1 Isolation and Structure of (+)-Discodermolide 
    (+)-Discodermolide (1.1, Figure 1.1) is a polyketide natural product isolated from the 
Caribbean deep-sea marine sponge Discodermia dissoluta by Gunasekera and co-workers 
in 1990.1 The isolation yield was only 0.002 % (7 mg from 454 g frozen sponge) and to 
date fermentation to produce (+)-discodermolide has not been successful. 
 
Figure 1.1 Structure of (+)-Discodermolide 
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    The structure of (+)-discodermolide was determined based on a series of NMR 
analyses, including 1H, 13C, COSY and a battery of 2D correlation experiments. (+)-
Discodermolide is composed of a 24-carbon linear polypropionate chain containing 13 
stereogenetic centers (4 hydroxyls and 7 methyl groups).1 The backbone of the natural 
product is punctuated by (Z)-olefinic linkages at C-8/C-9, C-13/C-14 and a terminal diene 
at C-21/C-22. (+)-Discodermolide adopts a U shape in the solution with the internal Z 
olefins acting as conformational locks by minimizing allylic strain and syn-pentane 
interactions along the backbone.2 The structure of (+)-discodermolide also features a 
carbamate and a tetrasubstituted δ-lactone with a boat-like conformation. The relative 
stereochemistry of (+)-discodermolide was determined by X-ray crystallographic analysis 
by Gunasekera and co-workers. However, the absolute stereochemistry of the natural 
product remained unknown until later confirmed by Schreiber and co-workers when they 
completed the first total synthesis of (–)-discodermolide in 1993.3 
 
1.1.2 Biological Activity of (+)-Discodermolide 
    Initial biological studies carried out by Gunersekera and co-workers demonstrated that 
(+)-discodermolide is a potent immunosuppressive compound both in vitro and in vivo.4 
Specifically, (+)-discodermolide can suppress the proliferative response of splenocytes 
and human peripheral blood leukocytes in the two-way mixed lymphocyte reaction with 
an IC50 at low micromolar level, and as such is equally effective as clinical approved 
cyclosporin A. In addition, (+)-discodermolide has low nanomolar anti-tumor efficacy 
towards a variety of human cancer cell lines, as reported by Lonely and co-workers.5 
More importantly, Schreiber and co-workers discovered that (+)-discodermolide retains 
 3 
the cytotoxicity against both taxol-resistant and multi-drug-resistant cell lines with high 
water solubility (100-fold greater than taxol), which makes it a promising candidate as 
anti-tumor drug.6,7 
    In terms of the mechanism of action, (+)-discodermolide was found by researchers at 
Harbor Branch, Florida to be a highly potent microtubule-stabilizing agent.7 It binds to 
the taxane pocket of β-tubulin and promotes tubulin polymerization, resulting in mitosis 
arrest at the G2 and M-phase that eventually leads to cell death. (+)-Discodermolide also 
promotes assembly of microtubules faster and more potently than any of the other know 
microtubule-stabilizing agents.7,8 In 2000, Horwitz and co-workers discovered the 
synergistic interaction between (+)-discodermolide and taxol in vitro and in vivo,9 
suggesting a promising combination for chemotherapy, although it was Schreiber and co-
workers who demonstrated that the competitive binding between (+)-discodermolide and 
taxol.10 Finally, the precise binding model of (+)-discodermolide with tubulin at the 
molecular level was only recently disclosed by the Steinmetz group in 2017.11 
 
1.1.3 Previous Syntheses of (+)-Discodermolide 
     The impressive biological profile of (+)-discodermolide and the scarce availability 
from the natural sponge material have over the years stimulated intensive synthetic study 
towards the natural product. Recognizing the repeating methyl-hydroxy-methyl 
stereochemical triad embedded in the target, each synthesis disconnected the natural 
product into three fragments of similar or equivalent complexity. 
 4 
    The first total synthesis of the unnatural antipode (–)-dicodermolide was reported by 
Schreiber and co-workers in 1993, which established the absolute configuration of the 
natural product.3 The synthesis was completed with an overall yield of 3.2% and 24 steps 
for the longest linear sequence. Later they prepared (+)-discodermolide. Subsequently in 
1995, the Smith group published their first-generation synthesis of (–)-dicodermolide 
with a 2.0% overall yield and a longest linear sequence of 29 steps, that featured a triple 
convergency strategy from a common precursor.12 Later in 1999, 1.043 gram of (+)-
discodermolide was prepared by the Smith group employing an improved second-
generation synthetic route with an overall yield of 6.0% and a longest linear sequence 21 
steps.13 The Smith fourth-generation synthesis was then reported in 2005 with an 
impressive improvement in overall yield to 9.0% with only 17 steps for longest linear 
sequence.14 This approach is both highly efficient and convergent, overcoming the 
previous problem in the preparation of a Wittig salt fragment. In 2000, the Paterson group 
reported their first synthesis of (+)-discodermolide employing a stereo-controlled aldol 
disconnection.15 They arrived at their third-generation approach via a Still-Gennari 
olefination with a longest linear sequence 21 steps and in 11.1% overall yield.16 
Early in 2004, Novartis prepared 60 grams of (+)- discodermolide for phase I clinical 
trial.17 The route they used was the hybrid of the Smith gram-scale route and endgame of 
the Paterson first-generation synthesis. The most recent synthesis of discodermolide came 
from Morken and coworkers in 2014.18 The synthesis featured catalytic stereoselective 
borylations developed in their group with the longest linear step count of 17 and in 13% 
overall yield. 
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1.1.4 The Structure-Activity Relationship Study of (+)-Discodermolide Analogs 
More than 200 analogs of (+)-discodermolide have been prepared by researchers from 
academia and industry for structure-activity relationship (SAR) study since it was 
isolated in 1990. (+)-Discodermolide could be divided into five regions (A-E) in terms of 
discussing the SAR study (Figure 1.2). All the analogs feature modifications either in one 
region or several regions at the same time.  
Analogs with modifications in region A were first investigated. Compounds with 
attachment of linkers or fluorescent probes to the terminal diene moiety displayed similar 
potency as the parent molecule,19 indicating that there is space to attach large groups in 
this domain. The reduction of internal olefins reduced the bioactivity dramatically, 
suggesting that it may be required for the high potency. A variety of analogs have been 
made with modifications at the carbamate region in which the aryl or alkyl groups were 
attach to the nitrogen.20 Almost all these analogs have equivalent or better (3-10 folds 
increase) potency, except the loss of activity in the cell lines with the P-glycoprotein 
efflux pump. Region B thus is another potential domain to introduce substituents to tune 
the pharmacokinetic properties. The skeleton C-17 through C-11 is necessary to retain the 
potent cytotoxicity as the acetylation of the hydroxyls or epimerization of stereocenters 
led to the loss of bioactivity.21 The 16-demethyl analog has a slight increase of the 
potency which may be taken advantages of in the design of simplified analogs.22 The 
olefins at C-13/C-14 and C-8/C-9 have significant impacts on the activity, possibly 
because they are required to set the conformation of the molecule.23 Region E has the 
most modifications so far with promising results. The alkylation or acetylation of C-7 
hydroxy has very positive effect on the potency (2-10 folds increase),29 suggesting 
 6 
possibly there is no hydrogen bond interaction involved with this hydroxyl. The 
substituents on the lactone ring are not necessary which results in simplified analogs with 
similar or better potency.29 
In summary, the diene system, the carbamate and the lactone moiety provide 
opportunities to design promising analogs with higher potency and better 
pharmacokinetic parameters. Considering the complexity of the molecule, the SAR study 
may help to develop simplified analogs which is valuable as total synthesis is the only 
method to access the molecule so far.  
Figure 1.2 Structure-activity Relationship Study of (+)-Discodermolide Analogs 
 
 
1.2 Rational Design of (+)-Discodermolide Analogs 
Because of the impressive biological profile of (+)-discodermolide as a promising anti-
tumor drug, chemists from Novartis prepared 60 gram of the natural product and 
completed a Phase I clinical oncology trial in 2004. (+)-Discodermolide displayed some 
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significant efficacy with disease stabilization for seven patients out of thirty. 
Unfortunately, the trial was discontinued due to the pneumotoxicity in three patients out 
of thirty-two after 4-5 cycles of drug treatment at higher dose levels.24 
In 2005, the Smith and Horwitz groups characterized (+)-discodermolide as a potent 
inducer of chemotherapy induced senescence (CIS), while taxol was a weak inducer.20 
Chemotherapy induced senescence (CIS) is defined as prolonged exit from proliferation 
that is distinct form quiescence, which has been shown to be a harmful therapeutic fate.21 
Later in 2014, Smith and Horwitz hypothesized that the chemotherapy induced 
senescence contributed to the fatal pneumotoxicity in the Novartis phase I clinical trial of 
(+)-discodermolide.27 Based on this hypothesis, we set out to look for analogs with lower 
risk of CIS, but that would have higher anti-tumor efficacy. 
According to a metabolic study in human liver microsomes by Day and co-workers, 
the lactone moiety and terminal diene of (+)-discodermolide were the most metabolically 
labile sites.28 Specifically, the lactone may undergo net oxidation and form a double bond 
at C-4 and C-5 position; the terminal diene moiety could also yield a diol after 
epoxidation followed by hydrolysis. During this metabolic process, the generation of 
reactive oxygen species may be associated with senescence induction. To this end, we 
hypothesized that analogs with enhanced metabolically stability may reduce the 
chemotherapy induced senescence leading to a less toxic drug candidate. 
For a structure-activity relationship study of (+)-discodermolide, we were interested in 
the degree of saturation at the terminal diene system, with different substitutions at the C-
7 position and modification of lactone moiety (Figure 1.3). Early studies demonstrated 
that analogs with a saturated C-(23, 24) terminal system and a simplified lactone moiety 
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had enhanced cytotoxicity with reduced induction of senescence relative to (+)-
discodermolide,29 possibly due to the fact that the modified compound is more resistant to 
oxidative metabolism. Therefore, we chose to prepare analogs with different saturation 
degrees at the terminal diene system (i.e., diene, monoene and saturated) to investigate 
the influence on stability and cytotoxicity. In terms of the lactone moiety, we were also 
interested in a simplified six-member ring lactone, and as well as a more rigid five-
member ring lactone.30 We also wished to evaluate analogs with one more methyl group 
at the C-4 position of lactone fragment, potentially blocking possible oxidative 
metabolism of the C-(4, 5) bond. According to literature precedence, the substitution at 
the C-7 position also has very positive effects on the cytotoxicity (i.e., 2-10 fold 
improved activity).31 This finding may be explained by the fact that the substitution is 
situated just above C-(4, 5) bond thus introducing steric hindrance for potential 
oxidations. To this end, we planned to synthesize analogs with different ether 
substitutions at the C-7 position, such as alkyls, methoxymethyl ether, acetate or 
carbamate groups. To summarize, we hypothesized that the potential designed analogs 
would be more resistant to oxidative metabolism, and thus with reduced senescence 
induction, but at the same time could retain or have improved cytotoxicity. 
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Figure 1.3 The Rational Design of (+)-Discodermolide Analogs 
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Scheme 1.1 Retrosynthetic Analysis of Butyrolactone Analogs 
 
 
From the retrosynthetic perspective, disconnection at the C-8/C-9 Z-olefinic linkage of 
butyrolactone analogs would lead to Wittig phosphonium salt 1.4 and butyrolactone 1.3. 
The lactone fragment 1.3 could then be tracked back to intermediate epoxide 1.13. Wittig 
salt fragment 1.4 in turn could be constructed via a Suzuki coupling protocol of alkyl 
iodide 1.6 and vinyl iodide 1.7.14 Importantly, both coupling partners could be derived 
from the same common precursor 1.5, which would be prepared from the (S)-Roche ester. 
This common precursor strategy is a notable feature of Smith discodermolide synthesis, 
permitting access to complex fragments in a highly convergent and efficient way. 
Novartis employed this strategy in their 60-gram synthesis of (+)-discodermolide.17 
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1.3.2 Synthesis of Lactone Fragment 1.3 
 
Scheme 1.2 Synthesis of Lactone Fragment (-)-1.3 
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    The synthesis of lactone fragment (-)-1.3 began with protection of commercially 
available (R)-glycidol (+)-1.8 as a benzyl ether. The organocuprate was then prepared in 
situ to open the epoxide regioselectively,32 followed by TBS protection of the 
homoallylic alcohol (+)-1.10. Epoxidation of alkene formed two diastereomers (anti: 
syn=1.5:1), which were subjected to Jacobsen hydrolytic kinetic resolution28 to provide 
the desired anti diasteroemer  (-)-1.13. Opening the epoxide with diethyl malonate 
followed by spontaneous cyclization afforded α-ethoxylcarbonyl lactone (-)-1.14. 
Pleasingly the Krapcho decarboxylation34 mediated by LiCl proceeded in 93% yield with 
the silyl group removed at the same time. The TBS protective group was then reinstalled, 
followed by the hydrogenolysis of benzyl ether to deliver primary alcohol (-)-1.16. Swern 
oxidation35 of the alcohol was then accomplished to furnish the target aldehyde (-)-1.3. 
Alcohol (-)-1.15 was also subjected to methylation36, hydrogenolysis and an oxidation 
sequence to provide lactone (-)-1.17. Other lactones with different alkyl groups on C-7 
position can also be prepared following this route for the future synthesis of analogs with 
different C-7 substitutions.  
 
 
 
 
 
 
 13 
1.3.3 Synthesis of Wittig Salt Fragment 1.4 
Scheme 1.3 Initial Approach to Wittig Salt Fragment 
 
 
 
 
For the synthesis of Wittig salt 1.4, advanced intermediate 1.17, available in the Smith 
group, required that the two PMB protective groups to be selectively deprotected. The 
initial strategy involved removal of both PMB groups and the resultant primary hydroxyl 
1.18 to be reprotected selectively as pivalate ester (Scheme 1.3). The free secondary 
alcohol 1.19 was then reprotected using PMB trichloroacetimidate catalyzed by a Lewis 
acid. Reductive cleavage of pivaloyl group delivered the desired alcohol 1.21. While 
carrying on with this route, we were pleased to discover that the primary PMB group 
could be removed selectively with the BCl3.DMS complex at 0 oC in good yield (Scheme 
1.4).37 With alcohol 1.21 in hand, the corresponding iodide 1.22 was then obtained 
followed by a modified Corey protocol.38 The unstable iodide was next heated with 
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excess PPh3 and DIPEA to provide the requisite Wittig phosphonium salt 1.4. Wittig salt 
fragment 1.24 with a MOM protective group on C-11 hydroxyl was later prepared for the 
synthesis of other analogs given our concern with the low yielding step from 1.22 due to 
a cyclization byproduct.39 
 
Scheme 1.4 Synthesis of Wittig Salt Fragment 1.4 
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1.3.4 Wittig Union and Final Elaborations 
Scheme 1.5 Wittig Union and Final Elaborations 
 
 
 
Having access to lactone 1.3 and Wittig salt 1.4, we turned to the key union and final 
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followed by global deprotection completed the synthesis of the butyrolactone analog 1.2. 
Pleasingly, analog 1.2 displayed comparative biological activity across a range of cancer 
cell lines compared to (+)-discodermolide according to data from the biological assays. 
 
1.4 Biological Evaluation of (+)-Discodermolide Analogs 
Figure 1.4 Analogs Prepared for Biological Evaluations 
 
 
O OH OH
HO
O
NH2
O
O
A1
O OH OH
HO
O
NH2
O
O
A2
O OH OH
HO
O
NH2
O
O
A3
O OH OH
HO
O
NH2
O
O
B1
O OH OH
HO
O
NH2
O
O
B2
O OH OH
HO
O
NH2
O
O
B3
O OH
O
O
OH
HO
O
NH2
C1
O OH
O
O
OH
HO
O
NH2
C2
O OH
O
O
OH
HO
O
NH2
C3
O
O
O
O
O
O
Diene                                                                 Monoene                                                               Saturated
 17 
Working together with Dr. Boying Guo who prepared the other eight novel analogs, a 
series of (+)-discodermolide analogs (Figure 1.4) with different degrees of saturation in 
the terminal diene system and with different lactone fragments have now been prepared 
for biological evaluation. In collaborations with professors Susan B. Horwitz and Hayley 
M. McDaid at the Albert Einstein College of Medicine, all analogs have been evaluated 
in cell proliferation assays with different cancer cell lines (especially triple negative 
breast and ovarian cancer cell lines which are typically taxane-resistant) employing 
multiparameter dose-response analysis (EC50, Emax, AUC) to compare the pharmacologic 
properties.40 According to these results, saturated analogs (A3, B3 and C3, Figure 1.4) 
had weaker anti-tumor activity compared to the monoene (A2, B2 and C2) and diene (A1, 
B1 and C1) series; however monoenes (A2 and B2) have superior activity compared to 
diene analogs (A1 and B1). In terms of the lactone, the geminal dimethyl analogs (A1-
A3) only have a subtle difference in activity relative to the B series with one methyl at 
the C-4 position in the lactone ring, while analogs with a butyrolactone group have 
reduced anti-tumor activity compared to the A or B series. Together with additional 
analysis of activity in taxol-resistant cell models, compound B2 with the monoene and a 
simplified lactone was identified as the lead analog for future study. Importantly, B2 
displayed superior long-term anti-tumor efficacy and anti-metastatic properties relative to 
(+)-discodermolide and to Taxol in cell proliferation assay. 
An equally important goal of this project is to evaluate the chemotherapy induced 
senescence (CIS) response of novel (+)-discodermolide analogs.  Lead analog B2 had 
significantly reduced CIS compared with (+)-discodermolide at 50 nm, although the 
phenotype activity was detectable at a lower dose.40 As we hypothesized that 
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chemotherapy induced senescence contributes to the fatal pneumotoxicity in the phase I 
clinical trial of (+)-discodermolide, we believed that analog B2 with lower risk of CIS but 
superior anti-tumor efficacy is a promising lead drug. 
 
1.5 Future Directions 
    As one of the most potent types of microtubule-stabilizing agents, the outlook of (+)-
discodermolide and the analogs therefore remain promising, and thus continues to 
stimulate research from chemists and biologists.    
    In 2017, Steinmetz group reported the first high-resolution crystal structure of (+)-
discodermolide in complex with tubulin (Figure 1.5) that revealed detailed binding modes 
of this natural product in the taxane pocket of β-tubulin.11 
    According to the crystal structure published by Steinmetz and co-workers, (+)-
discodermolide was buried deeply in the taxane site of β-tubulin (A, Figure 1.5), 
possessing a very similar hairpin conformation as was observed in solid-state and 
solution NMR studies. However, the lactone ring in the crystal structure of the complex is 
a in half-chair conformation. There are five main hydrogen bonds: C-1 ester carbonyl and 
Ser232; C-3 hydroxy and Arg369; C-11 hydroxy and Asp226; C-17 hydroxy and 
Pro274/Thr276; carbamate with Leu371. In addition, the terminal diene system of (+)-
discodermolide has a weak hydrogen bond to Thr276 and a π-π interaction to Arg278. 
The detailed binding model lends some support to the previous structure-activity 
relationship studies (i.e. hydroxyls at C-11 and C-17 are important, and the lactone and 
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the carbamate moiety are required for high potency) and permits rationalization of the 
retention of cytotoxicity again taxol-resistant cancer cell lines. 
 
Figure 1.5 Crystal Structure of (+)-Discodermolide-tubulin Complex 
 
A) Overall view of (+)-discodermolide-tubulin complex 
B) Detailed view of (+)-discodermolide-tubulin complex  
     
Having identified B2 (Figure 1.4) as a lead compound, we hoped to gain insights into 
the molecular binding mechanism of this analog in the taxane pocket for the future design 
of novel (+)-discodermolide analogs. In collaboration with professor Michel O. 
Steinmentz, we were pleased very recently to learn of the crystal structure of the B2 
analog in complex with β-tubulin at a level of 2.0 Å resolution (Figure 1.6).40 In the 
taxane pocket, the B2 analog adopted a very similar hairpin structure and conserved most 
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of the interactions as (+)-discodermolide (A, Figure 1.6). However, the simplified six-
member lactone led to the loss of one hydrogen bond to Arg369 (B, Figure 1.6). 
Reorientation of the lactone ring in the taxane site was also observed. Moreover, there is 
a small reorientation of monoene moiety in the B2 analog resulting in a minor shift of 
Arg278 sidechain. These observations may rationalize the superior bioactivity of B2 
analog due to a more favorable occupation in the binding site of β-tubulin relative to (+)-
discodermolide.  
 
Figure 1.6 Crystal Structure of B2-Tubulin Complex 
 
A) Detailed view of B2 analog-tubulin complex 
B) Close-up view of superimposed (+)-discodermolide-tubulin complex (violet purple) 
 
Although we have gained some structural insights into the binding modes, we still 
cannot yet completely understand the better bonding affinity of B2 analog. To this end, 
Dr. Boying Guo has designed two new analogs 1.26 and 1.27 (Figure 1.6) for better 
understanding of binding mechanism. Compared with the B2 analog, both 1.26 and 1.27 
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have a monoene system but different lactone fragments: one has one methyl on C-2 (1.26, 
Figure 1.6) and the other has a hydroxy group on C-3 (1.27, Figure 1.6). Once 
synthesized, we would like to obtain the crystal structure of analog 1.26 and 1.27 
complexed with tubulin to understand which (monoene moiety or lactone fragment) 
causes the more favorable binding of B2 with tubulin. Only with better understanding of 
the binding modes, will we be able to design new analogs of (+)-discodermolide as drug 
candidate by fully exploiting the landscape of the taxane site. 
 
Figure 1.7 Novel (+)-Discodermolide Analogs 
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CHAPTER 2. SYNTHETIC STUDY TOWARDS (–)-PTEROCIDIN: A “HIGH-
RISK” VENTURE 
 
2.1 Introduction 
 
2.1.1 Isolation and Structure Elucidation of (–)-Pterocidin 
2.1.1.1 Isolation of (–)-Pterocidin 
(–)-Pterocidin (2.1, Figure 2.1), a cytotoxic compound from endophytic Streptomyces 
hygroscopicus TP-A0451 strain, was isolated by Igarashi and co-workers in 2006.1 In 
2012, they rediscovered (–)-pterocidin from Streptomyces sp. TP-A0879 in a marine 
sediment sample collected at Otsuchi Bay in Japan.2 With sufficient material (36 mg 
natural product after HPLC purification) in hand, Igarashi and co-workers established the 
absolute stereo-configuration of (–)-pterocidin based on a series of NMR analyses and 
chemical derivatizations.  
Figure 2.1 Structure of (–)-Pterocidin 2.1 
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(–)-Pterocidin1 (2.1, Figure 2.1) is a linear polyketide featuring an α, β-unsaturated γ-
oxygenated δ-lactone terminus with five stereogenetic centers. It also has a highly 
unsaturated aliphatic chain with a dienyl ether moiety. Although the chiral α, β-
unsaturated δ-lactone motif is not unusual in bioactive natural products, (–)-pterocidin is 
the first in this class to have a methoxy substitution on the lactone ring. The structure of 
(–)-pterocidin is closely related to several other members in this class of natural products 
isolated from Streptomyces species, including fostriecin3, cytostatin4 and pironetin5 et al. 
 
2.1.1.2 Structure Elucidation of (–)-Pterocidin     
The molecular formula of (–)-pterocidin 2.1 was first established by 13C NMR and 
HRFAB-MS analysis.1 According to the 1H, 13C, HMQC, DEPT NMR spectra and 
IR/UV absorption spectra, the molecular composition and functional groups of 2.1 were 
determined. DQF-COSY and HMBC correlations studies revealed the connectivity along 
the carbon skeleton. Coupling constants were then used to establish the trans 
configurations for C-6/C-7, C-8/C-9, and C-16/C-17, as well as the cis configurations for 
C-2/C-3. Equally important, strong NOESY correlations suggested the cis configuration 
for C-4/C-5. 
In terms of the absolute configurations,2 Igarashi and co-workers began with Mosher’s 
ester derivatization analysis to establish and confirm the absolute configurations of C-13 
as S. Based on a series of J-based analyses and NOESY analyses, they assigned the C-10 
as S and C-12 as R configuration. The coupling constant between protons at C-4 and C-5 
as well as the NOE between these protons suggested the syn relationship. (–)-Pterocidin 
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2.1 was also reduced with Ca(BH4)2 and the corresponding tris-MPA ester was prepared, 
permitting establishement of the R configurations for C-5 and thus the R configurations 
for C-4. 
 
2.1.2 Biological Activity of (–)-Pterocidin 
Similar to other polyketides with δ-lactone rings isolated from actinomycetes, (–)-
pterocidin1 2.1 has antiproliferative activity towards different cancer cell lines with IC50 
values ranging from 2.9 to 7.1 μM (Table 2.1). More importantly, (–)-pterocidin has 
potent anti-invasive activity at non-cytotoxic concentrations. Specifically, the invasion of 
murine colon 26-L5 carcinoma cells across the Matrigel-fibronectin membrane can be 
inhibited by (–)-pterocidin with an IC50 value of 0.25 μM, while the cytotoxicity is not 
apparent with concentrations up to 7 μM.  
Tumor cell invasion comprises a key feature of metastasis, which significantly reduces 
survival rates and the prognosis of patients, and thus is the most common cause of death 
in cancer patients. However, the current market is still without this type of effective drug. 
That is, anti-invasion agents are in great demand as a complement to and improved 
options for innovative cancer therapy. As the first example with potent anti-invasive 
activity in this class of natural products, we were very interested in the possibility of a 
structure-activity relationship study of (–)-pterocidin for future drug development. 
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Table 2.1 Cytotoxity of (–)-Pterocidin Against Different Cancer Cell Lines 
Cancer Cell Line NCI-H522 OVCAR-3 SF539 LOX-IMVI 
IC50 (μM) 2.9 3.9 5.0 7.1 
 
 
 
2.2 Retrosynthetic Analysis of (–)-Pterocidin 
 
2.2.1 Strategic Disconnection of (–)-Pterocidin 
Retrosynthetically, we envisioned the endgame construction of (–)-pterocidin to 
comprise methylation, desulfurization and TMS removal of the dithiane precursor (+)-
2.2. This advanced intermediate in turn would be constructed via a late-stage union of 
aldehyde fragment (–)-2.3, bifunctional linchpin (–)-2.5 and a dienyl ether fragment 2.4 
employing the Type II Anion Charge Relay (ARC) tactic (Scheme 2.1) developed in the 
Smith group. Continuing with this analysis, disconnection of the diene side chain and 
lactone moiety in aldehyde fragment (–)-2.3 leads to alkene (–)-2.16. The Smith group6 
has developed a six-step synthesis of enantiopure linchpin (–)-2.5 from commercially 
available (S)-Roche ester. The 1,3-dienyl ether 2.4 in turn would derive from olefin 2.26 
via a 1,4-elimination.7 
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Scheme 2.1 Retrosynthetic Analysis of (–)-Pterocidin 2.1 
 
 
 
Such a convergent strategy would hold the promise not only to access (–)-pterocidin 
but potentially other analogs for a structure-activity relationship study, via late-stage 
assembly of carbon skeleton and early-stage flexible adjustment of each coupling 
fragment. This strategy exploiting the Type II ARC tactic can also be applied to the 
synthesis of other members in this class of natural products, featuring a δ-lactone 
terminus and unsaturated polyene chains such as cytostatin4 (Scheme 2.2). 
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Scheme 2.2 Proposed Synthetic Strategy Employing Type II ARC of Cytostatin 
 
 
 
 
2.2.2 Key Union: A Showcase for Type II Anion Relay Chemistry (ARC) 
    In the above proposed retrosynthetic disconnection of (–)-pterocidin, the key fragment 
union was clearly designed as a “high-risk” showcase for Type II Anion Relay Chemistry 
(ARC) exploiting the bifunctional linchpin (–)-2.5 recently developed in the Smith group 
(Scheme 2.3).  
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Scheme 2.3 Key Fragment Union Employing Type II ARC Tactic 
 
 
 
    Addition of a metallated dienyl ether such as 2.4 to the enantiopure linchpin aldehyde 
(–)-2.5 (Scheme 2.3) was anticipated to proceed via Felkin-Anh8 diastereoselective 
control to form the syn addition product, lithium alkoxide 2.41. Upon addition of HMPA, 
a 1,4-Brook rearrangement9 could then be triggered to reveal the dithiane-stabilized 
carbanion 2.42, which would be trapped in situ by aldehyde fragment (–)-2.3 to furnish 
the highly functionalized intermediate (+)-2.2 as the tricomponent adduct. 
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2.2.3 Type II Anion Relay Chemistry and Its Application in Natural Product Synthesis 
Over the past decade, the Smith group has reported extensive studies on the 
development and application of the highly efficient, multicomponent Anion Relay 
Chemistry (ARC)10 tactic. Anion relay chemistry features in “one-flask” a multiple 
fragment union tactic by controlling the migration of negative charge, employing a 
linchpin as the center component. This strategy permits the formation of multiple C-C 
bonds in a “single” flask reaction, thus having access to the rapid and efficient assembly 
of highly functionalized intermediates found in architecturally complex biologically 
active molecules synthesis. Equally important, with facile structural variations pre-
installed in each fragment prior to their union, the anion relay chemistry can lead to a 
convergent synthetic route that holds considerable potential for diversity-oriented 
synthesis (DOS)11. 
Anion relay chemistry has more recently evolved into Type I and Type II ARC union 
tactics (Scheme 2.4)10. In Type I ARC, an anion is first generated in the linchpin with 
anion-stabilizing group followed by addition of an electrophile (i.e., an epoxide) to 
generate the lithium alkoxide. Upon triggering a Brook rearrangement by changes of 
solvent polarity, temperature and/or counterion, the negative charge on the oxygen is 
relayed back to the original carbon site, followed by electrophilic termination to provide 
the tricomponent adduct. In Type II ARC, an external nucleophile first adds to a 
bifunctional linchpin to form the lithium alkoxide. The negative charge on the oxygen is 
then migrated to a new distal carbon center via a Brook rearrangement, which is further 
captured by electrophiles to deliver tricomponent adducts in a single flask. 
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Scheme 2.4 Type I and Type II ARC Tactics 
 
 
 
Recently, our group has developed a new aldehyde linchpin6 for the synthesis of 
propionate subunits in complex molecules exploiting the Type II ARC tactic (Scheme 
2.5). In this event, an external nucleophile first adds to the enantiopure aldehyde linchpin 
(–)-2.5 to form the lithium alkoxide. With an alpha substituent on the aldehyde, the 
nucleophilic attack is controlled by the Felkin-Anh model8 to furnish the syn adduct. 
Upon triggering the 1,4-Brook rearrangement, the negative charge on oxygen migrates to 
a distal carbon site leading to the dithiane anion, which is then trapped by electrophiles to 
deliver the tricomponent adduct with propionate units present. 
 
 
R’
O
ASG
SiR3
Linchpin R’
O
SiR3
ASG Brook
R’
R3SiO ASG E
R’
R3SiO ASG
E
Tricomponent 
Adduct
ASG
SiR3
R2
O Nu O
SiR3
ASG Brook R3SiO ASG
Nu Nu
E R3SiO ASG
E
NuR2 R2 R2Bifunctional 
Linchpin Tricomponent 
Adduct
ASG = Anion  Stabilizing Group              Nu = Nuclephile               E = Electrophile
Li
 35 
Scheme 2.5 New Aldehyde Linchpin for Type II ARC  
 
 
 
The Type II ARC tactic featuring this new aldehyde linchpin has been employed to 
great advantage recently by our group. In 2015, Dr. Mellilo and co-workers demonstrated 
the synthetic utility of this new protocol in the synthetic study toward C-16-C-19 
fragment of rhizopodin (A, Scheme 2.6).6  In this convergent synthetic route, the vinyl 
species derived from iodide 2.42 was added to the aldehyde linchpin (+)-2.5, followed by 
1,4-Brook rearrangement triggered by addition of HMPA and terminating the process 
with epoxide 2.43 to provide the desired tricomponent adduct 2.44 featuring the C-16-C-
19 carbon skeleton of rhizopodin.  Later in 2017, Dr. Liu and co-workers completed the 
first total synthesis of nahuoic acid Ci (Bii), in which the side chain was constructed via 
the Type II ARC tactic employing the new bifunctional linchpin (B, Scheme 2.6).12 In 
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this event, isopropyl lithium 2.45 first attacked aldehyde linchpin (+)-2.5 to form the 
lithium alkoxide. Upon 1,4-Brook rearrangement triggered by addition of HMPA, the 
generated carbon anion was trapped by epichlorohydrin 2.46 to furnish the intermediate 
2.47 as single diastereomer with a 76% yield on gram scale.  
 
Scheme 2.6 Recent Application of linchpin 2.5  
A. Key Union in the Synthesis of rhizopodin 
  
B. Side Chain Preparation of Nahuoic Acid Ci (Bii) 
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2.3 Synthetic Studies Towards (-)-Pterocidin 
 
2.3.1 Synthesis of Aldehyde Fragment (–)-2.3 
2.3.1.1 First-Generation Synthetic Approach To Aldehyde Fragment (–)-2.3 
    Retrosynthetically, aldehyde fragment (–)-2.3 can be accessed from alkene (–)-2.11 via 
ring-closing metathesis13 reaction. Alkene (–)-2.11 in turn could be assembled via a 
Brown14 alkoxyallylation of aldehyde 2.9 with subsequent acylation. Boeckman15 et al. 
has reported a scalable protocol for the synthesis of aldehyde 2.9 from commercially 
available sorbaldehyde 2.6 (Scheme 2.7). 
 
Scheme 2.7 First-Generation Retrosynthetic Analysis of Aldehyde (–)-2.3 
 
 
 
    Our synthesis thus began with commercially available 2,4-hexdienal 2.6 (E/Z mixture 
5:1) involving a condensation with diisopropyl tert-butylphosphonoacetate (Scheme 2.8). 
The Horner-Wadsworth-Emmons16 reaction was then successfully employed to afford the 
sensitive and unstable triene 2.7. The crude triene was next subjected to a regioselective 
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Sharpless catalytic dihydroxylation17 to furnish diol ester 2.8 which was converted to the 
aldehyde 2.9 by oxidation employing NaIO4. Followed Brown’s asymmetric 
alkoxyallylation14 technology, the γ-methyoxyallyl borane reagent generated in situ was 
added to the aldehyde 2.9 which resulted in the construction of the syn-stereocenters in 
2.10 both with good yield and stereoselectivity. Subsequent acylation led to ring-closing-
metathesis precursor (–)-2.11.  
 
Scheme 2.8 First-Generation Synthetic Approach to Aldehyde (–)-2.3 
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With alkene (–)-2.11 in hand, various conditions for the metathesis reaction were 
investigated including different temperatures (r.t. – 110 oC), solvents (DCM, toluene, 
CPME) and catalysts (A1 - A4, Table 2.2).18-20 However, the ring-closing metathesis 
reaction aiming to access α,β-unsaturated lactone 2.12 proceeded in unsatisfactory yields 
(10% - 15%). We reasoned that the methoxy group and the diene moiety in (–)-2.11 may 
chelate with the Ru carbene competitively resulting low conversion of the reaction. 
Unfortunately, no significant improvements were observed with either additives such as 
Ti(OiPr)420 and/or fast initiating catalysts (A3, A4, Table 2.2).19 We therefore decided to 
construct the lactone ring in 2.12 via ring-closing metathesis before the diene chain was 
installed. 
 
Table 2.2 Catalysts Screen of Ring-Closing Metathesis Reaction 
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and that the aldehyde in turn could be constructed from alkene (–)-2.16 via ring-closing 
metathesis, which would derive from aldehyde 2.14. 
Scheme 2.9 Second-Generation Retrosynthetic Analysis of Aldehyde (–)-2.3 
 
 
 
A second route was thus designed that begins with the commercially available 
aldehyde 2.14, which can also be synthesized via a two-step transformation beginning 
with ethylene glycol 2.13 (Scheme 2.9). Followed Brown’s asymmetric 
alkoxyallylation14 technology, the γ-methyoxyallyl borane reagent was generated in situ 
and added to the aldehyde 2.14 to construct the syn-stereocenters in (–)-2.15 with good 
yield and stereoselectivity (dr>95%, ee>90%). Subsequent acylation (a migration 
byproduct was observed, see experimental section) and ring-closing metathesis with the 
Hoveyda-Grubbs II generation catalyst18 (loading can be as low as 1.5% mmol) in 
toluene successfully delivered lactone (–)-2.17. Acidic removal of the TBS protecting 
group revealed the primary alcohol in good yield. However, oxidation of alcohol 2.22 to 
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Scheme 2.10 Second-Generation Synthetic Approach to Aldehyde (–)-2.3 
 
 
 
To obtain the aldehyde precursor necessary to install the diene side chain, an 
alternative route was developed via the conversion of lactone (–)-2.17 to the 
corresponding ethyl acetal 2.18 followed by oxidation (Scheme 2.10). Lactone (–)-2.17 
was then reduced by DIBAL-H to the lactol followed by conversion to the corresponding 
ethyl acetal 2.18. An alternative method to prepare acetal 2.18 via transketalizaiton23 of 
(–)-2.15 with acrolein diethyl acetal followed by ring-closing metathesis proved 
unrewarding, which was mostly attributed to the modest conversion (40% - 60%) of 
transketalization on large scale. To this end, deprotection with TBAF, followed by 
TEMPO mediated oxidation24 furnished the desired aldehyde 2.19.  
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likely because the product is unstable under those conditions. Reverse addition of 
deprotonated phosphonate to aldehyde or premixing aldehyde with phosphonate led to 
better yields (Entry 3, 6, Table 2.3). We next turn to investigate modified conditions with 
inorganic bases such as LiOH.H2O26 and Ba(OH)2.8H2O27 (Entry 7, 8, Table 2.3). 
Pleasingly, installation of the E, E-diene moiety in dienoate 2.20 was achieved using 
LiOH.H2O in the present of 4 Å molecular sieves with 60% yield. The tert-butyl dienoate 
proved advantageous for the following formation of the acid in the presence of a lactone; 
initially we prepared the corresponding methyl dienoate which proved to be problematic 
in the subsequent hydrolysis of the α,β-unsaturated lactone to form the acid (i.e., 1,2-
addition at the double bond of the unsaturated lactone or leading to decomposition). 
 
 
  Table 2.3 Optimization of Horner-Wadsworth-Emmons Olefination 
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Entry Base Temp. Conditions Result 
1 LiHMDS 0 oC Normal additiona, b 15% 
2 LiHMDS -78 oC Normal additiona, b 15% 
3 LiHMDS -78 oC Reverse additiona, c 35% 
4 NaH 0 oC Reverse additiona, c 20% 
5 n-BuLi -78 oC Reverse additiona, c  
6 LiHMDS -78 oC Premix 2.19 with phosphonate 30% 
7 LiOH.H2O 70 oC Reflux with 4 Å molecular sieves 60% 
8 Ba(OH)2.8H2O 70 oC Reflux with 4 Å molecular sieves 55% 
aThe phosphonate was deprotonated at -78 oC, stirred for 20 min at 0 oC. 
bThe aldehyde substrate 2.19 was added to deprotonated phosphonate. 
cThe deprotonated phosphonate was added to aldehyde substrate 2.19. 
 
    Lactal 2.12 was therefore next converted to corresponding lactone (–)-2.12 with 
purified m-CPBA28 as oxidant mediated by BF3.Et2O.29 Next, a TFA assisted tert-butyl 
group removal led to the carboxylic acid (–)-2.21 (Scheme 2.11). This acid was then 
treated with the Ghosez chloroenamine reagent30 to form the acid chloride, which was 
reduced in-situ to afford aldehyde fragment (–)-2.3. Pleasingly this route can be 
processed on the gram scale level with an 8% overall yield for the 11 steps from 
commercially available aldehyde 2.13. 
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Scheme 2.11 Second-Generation Synthesis of Aldehyde (–)-2.3 
 
 
 
 
2.3.2 Synthesis of 1,3-Dienyl Ether Fragment 2.4 
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steps. The resultant olefin geometry of the product can be rationalized by the fact that 
complex A is favored relative to complex B in the reaction (Scheme 2.12). 
 
Scheme 2.12 Synthesis of 1,3-Dienyl Ether Fragment 2.4 
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2.3.3 Fragment Union to Complete the Carbon Skeleton of (-)-Pterocidin 
 2.3.3.1 Generation of α-Lithiated 1,3-Dienyl Ether  
Having procured all three required fragments on reasonable scale, we began to explore 
the key union reaction exploiting Type II ARC strategy. We first investigated the 
metalation of the 1,3-dienyl ether 2.4 at α position. Preliminary results using s-
BuLi/TMEDA or t-BuLi as base33 proved unsatisfactory; no deuterium incorporation was 
observed upon a D2O quenching experiment. However, when dienyl ether 2.4 was treated 
with Schlosser’s base (n-BuLi/KOt-Bu) in THF at -78 oC, more than 90% deuterium 
incorporation at α position was observed.34 The methoxy group in dienyl ether 2.4 
presumably directs the lithiation reagent to the adjacent α-H, which has greater acidity 
due to the presence of the electronegative oxygen atom, resulting in regioselective 
deprotonation at the α position. 
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Scheme 2.13 Generation of α-Lithiated 1,3-Dienyl Ether 
 
 
Having generated the α-metalated dienyl ether, we proceeded to investigate the 
nucleophilic addition with linchpin aldehyde 2.5. Initial results proved unrewarding, 
possibly given that the aldehyde is not compatible with the very basic anion generated 
with Schlosser’s base (Scheme 2.13). Although transmetalation aiming to reduce the 
basicity is possible, it may complicate the subsequent Brook rearrangement process. In 
turn, we prepared both organostannane 2.29 and iodide 2.30 as possible precursors to 
generate α-lithiated 1,3-dienyl ether. Pleasingly, Li-I exchange35 with two equivalents of 
t-BuLi proved to be optimal, with inconsistent Li-Sn exchange using n-BuLi, which is 
possibly limited by the transmetalation equilibrium.36 
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2.3.3.2 First Stage of ARC Union: Nucleophilic Addition and Brook Rearrangement 
Having successfully generated the α-lithiated dienyl ether required for the nucleophilic 
addition of ARC union tactic,  the subsequent 1,4-Brook rearrangement was examined 
(Table 2.4).  Using less dissociating solvents such as diethyl ether for Li-I exchange and 
nucleophilic addition to aldehyde (–)-2.5, pre-Brook intermidate (+)-2.27 was captured in 
good yield (Entry 1, Table 2.4). As expected, addition of HMPA to increase the solvent 
polarity or the use of KOtBu for countercation exchange37 triggers the 1,4-Brook 
rearrangement at -78 oC to afford product (+)-2.28 (Entry 2-3, Table 2.4). Alternatively, 
in the presence of the more polar solvent THF, only Brook product (+)-2.28 was 
observed (Entry 4, Table 2.4). Both pre-Brook product (+)-2.27 and Brook product (+)-
2.28 were isolated as single diastereomer. The relative configuration of the pre-Brook 
product (+)-2.27 was assigned as syn according to Mosher ester NMR analysis,38 
confirming the Felkin-Ahn control in the nucleophilic addition between the anion 
precusor 2.30 and linchpin aldehyde (–)-2.5. The dithiane anion derived from Brook 
rearrangement was further validated with allylbromide as a terminating electrophile; very 
pleasingly tricomponent adduct (+)-2.31 was isolated in 80% yield. 
 
Table 2.4 Investigation of First Stage of ARC Union 
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Entry Solvent a Solvent b Additive Product 2.27 Product 2.28 
1 Et2O Et2O - 89% - 
2 Et2O Et2O HMPA - 75% 
3 Et2O Et2O KOtBu - 70% 
4 THF THF - - 75% 
 
 
 
2.3.3.3 Second Stage of ARC Union: Dithiane Anion Capture by Electrophiles 
With the encouraging results from the first stage of ARC union tactic achieved, we 
turned to investigate different electrophiles as the terminating component. Originally, we 
proposed acid chloride 2.32 as terminating electrophile for the ARC union (Scheme 
2.14). On the one hand, an acid chloride is a highly reactive electrophile towards many 
organometallic reagents for ketone synthesis. Thus, we hope to achieve chemoselective 
addition of fragment 2.32 in the present of other reactive functionalities such as α, β-
unsaturated lactone, diene and the acidic proton at C-5 in consideration of the potential 
elimination. More importantly, we might have the chance to control the stereochemistry 
at C-10 via a subsequent diastereoselective reduction if the desired adduct ketone 2.33 
could be obtained. 
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Scheme 2.14 Acid Chloride as Terminating Electrophile 
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pentafluorophenol or the Weinreb amide, Entry 6-8, Table 2.5) to construct ketone 2.33. 
However, nucleophilic acyl substitutions proved unsatisfactory. 
 
Table 2.5 Alternative Electrophiles Coupling Partners 
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    To this end, we turned to aldehyde (–)-2.3 as the terminating electrophile for the ARC 
union. When aldehyde was added to the dithiane anion derived from the Brook 
rearrangement, the nucleophilic addition proved unrewarding with an elimination 
byproduct isolated (see experimental section). This result may be attributed to the high 
reactivity of dithiane anion and the sensitivity of aldehyde fragment. We then reverse the 
addition order; that is, the dithiane anion was added to the aldehyde fragment, aiming to 
suppress side reactions with the electrophile. Pleasingly, we isolated a diastereomeric 
mixture of tri-component adduct 2.34 albeit the yield was ca. 40%. The diastereomeric 
ratio was approximately 1:1.5 and importantly the two diastereomers could be separated 
via medium pressure liquid chromatography. The absolute configuration of C-10 in the 
major diastereomer (+)-2.2 was determined via Mosher ester analysis (Table 2.7). To 
reduce the basicity of dithiane anion, we also tested transmetalation with LaCl3.2LiCl41 or 
ZnCl2, however the results were not rewarding due to concomitant retro-Brook 
rearrangements (Entry 5-6, Table 2.6). 
  
Table 2.6 Aldehyde (–)-2.3 as Terminating Electrophile 
 
 
 
OMe
I
Me
O
HTMS
S S
THF
-78 oC
t-BuLi
conditions
OOMe
O
O
H
THF, -78 oC
OMe
O
O
OMe
Me
Me
OTMSS S
OH
2.30
(—)-2.3
2.34
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Entry Anion 
Equivalent 
Conditions Yield 
1 0.5 THF, -78 oC <5% 
2 2 THF, -78 oC <10% 
3 2 aTHF, -78 oC 
 
38~42%, 52% brsm 
4 4 aTHF, -78 oC <5% 
5 2 aLaCl3.2LiCl, -78 oC <5% 
6 2 aZnCl2, -78 oC to 0 oC <5% 
a. Reverse addition: after linchpin was added, the reaction mixture was cannulated to aldehyde 2.3 (see SI) 
 
 
 
 
Table 2.7 Mosher Ester Analysis of (+)-2.2 
 
 
 
OOMe
O
O
OMe
Me
Me
OTMSS S
MTPA
4 7 9 14 19
+0.01
+0.01
+0.01 +0.02
+0.16
+0.06
+0.37
+0.03
-0.04
0.00
-0.01
0.00
-0.01
-0.02
0.00
-0.01
-0.03
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Nuleus S-ester δS (ppm) R-ester δR (ppm) δS–δR (ppm) 
2 6.18 6.17 +0.01 
3 6.97 6.96 +0.01 
4 4.03 4.02 +0.01 
5 4.99 4.97 +0.02 
6 5.96 5.80 +0.16 
7 6.44 6.38 +0.06 
8 6.53 6.16 +0.37 
9 6.10 6.07 +0.03 
12 1.91 2.13 –0.04 
13 5.05 5.05 0.00 
15 5.59 5.60 –0.01 
16 6.30 6.30 0.00 
17 5.65 5.66 -0.01 
18 2.11 2.13 -0.02 
19 1.02 1.02 0.00 
22 0.95 0.96 -0.01 
24 0.19 0.22 -0.03 
 
2.3.4 Late-Stage Elaboration of (–)-Pterocidin  
Having established the carbon skeleton and all stereocenters of the natural product, we 
proceeded to late stage elaboration to complete the synthesis. The advanced intermediate 
2.34 proved base and acid sensitive, due to the presence of the dienyl ether and lactone 
moiety. Indeed, methylation tactics under basic or acidic conditions (Entry 1-4, Table 
2.8) all failed. The mild and almost neutral condition employing silver oxide42 and 
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methyl iodide, however, was promising. In fact, we were able to achieve the methylation 
with excess silver oxide even in consideration of the steric hindrance around C-10 
hydroxyl group in advanced intermediate 2.34.  
 
Table 2.8 Optimization of Late Stage Methylation Reaction  
 
 
Entry Base Methylation Reagent Result 
1 NaH MeI messy 
2 LiHMDS MeI no reaction 
3 2,6-di-tert-butyl-pyridine MeOTf messy 
4 proton sponge Me3OBF4 messy 
5 Ag2O (5eq) MeI (excess) no reaction 
6 Ag2O (50eq) MeI (excess) 60% 
 
Next, TBAF mediated removal of silyl ether protective group delivered compound 
2.36 (Scheme 2.15). The last step to complete the synthesis is now to reduce dithiane 
moiety at C-11 to methylene. However, this transformation is quite formidable given the 
OMe
O
O
OMe
Me
Me
OTMSS S
OH OMe
O
O
OMe
Me
Me
OTMSS S
OMe
conditions
2.34 2.35
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presence of multiple double bonds, α, β-unsaturated and a dienyl ether. We first explored 
Raney nickel43 as reducing agent, but this tactic only leads to decomposition. Currently 
the t-Bu3SnH44 and NiCl2/NaBH4 system are under investigation for final desulfurization. 
 
Scheme 2.15 Late Stage Elaboration of (–)-Pterocidin 
 
 
 
 
2.4 Summary 
 
To date, the aldehyde fragment (–)-2.3, the bifunctional linchpin (–)-2.5 and the dienyl 
ether 2.30 fragment have been prepared on significant scale. The key union of the three 
fragments via ARC has also been achieved resulting in advanced intermediate (+)-2.2 
with all correct stereogenicities established for the natural product (Scheme 2.15). 
However, the yield of the union reaction is currently only 40%; optimization of this 
OMeOMe
O
O
OMe
Me
Me
OH
OHOMe
O
O
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Me
Me
OTMSS S
(+)-2.2
MeI, Ag2O
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̶
OMeOMe
O
O
OMe
Me
Me
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(—)-2.37
OMeOMe
O
O
OMe
Me
Me
OHS S
2.36
TBAF
60%
Raney Ni
(—)-Pterocidin 2.1
or Bu3SnH
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reaction is ongoing. The synthesis of aldehyde fragment (–)-2.3 takes 11 steps from a 
commercially available aldehyde with an overall yield of 8%. The synthesis of linchpin 
(–)-2.5 aldehyde comprised a six-step transformation from (S)-Roche ester with an 
overall yield of 55%. The dienyl ether fragment 2.30 was next prepared via modification 
of a literature procedure, which takes five steps with a total yield of 49%.  
    Current studies are directed at the optimization of the tri-component union reaction to 
improve the yield and stereoselectivity. The late-stage desulfurizaiton is under 
investigation followed by completion of the total synthesis of (–)-pterocidin 2.1.  
    Concerning the potent anti-invasive activity of (–)-pterocidin, more analogs will be 
designed and synthesized for further biological and medicinal study. The lactone moiety 
can be replaced by de-methoxy six/five-member ring lactone or aryl rings with different 
substituents. The simple enol ether analogs will also be investigated.  
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Chapter 3. EXPERIMENTAL PROCEDURE AND SPECTROSCOPIC DATA 
 
3.1 Experimental Section Relevant to Chapter One 
 
3.1.1 Materials and Methods 
Reactions were performed either in flame or oven-dried glassware under a nitrogen 
atmosphere unless noted otherwise. Anhydrous diethyl ether (Et2O), tetrahydrofuran 
(THF), dichloromethane (CH2Cl2) and toluene were obtained from a solvent purification 
system. Triethylamine, diisopropylethylamine and pyridine were freshly distilled from 
calcium hydride under a nitrogen atmosphere. All chemicals were purchased from 
commercial vendors, unless otherwise referenced. Reactions were magnetically stirred 
unless stated otherwise and monitored by thin layer chromatography (TLC) with 0.25 
mm pre-coated silica gel plates. Silica gel chromatography was performed utilizing ACS 
grade solvents and silica gel. Preparatory TLC was performed using 500 μm pre-coated 
silica gel plates and ACS grade solvents. Medium pressure liquid chromatography was 
conducted by using a medium pressure pump equipped with a high pressure glass column 
(350 mm ÅL 35 mm or 350 mm Å~ 10 mm) packed with silica gel (Standard Grade, 
porosity 60 Å, particle size 32-63 μm). Infrared spectra were obtained using a FT/IR plus 
spectrometer. Optical rotations were obtained using a polarimeter at 589 nm. CD spectra 
were obtained using a circular dichroism spectrometer in a 1 mm quartz cell. 1H NMR 
spectra (500 MHz field strength) and 13C NMR spectra (125 MHz field strength) were 
obtained on a 500 MHz spectrometer or a cryomagnet (500MHz/52mm) with a 5 mm 
dual cryoprobe. Chemical shifts are reported relative to chloroform (δ 7.26), benzene (δ 
7.16) or methanol (δ 3.31) for 1H NMR spectra and chloroform (δ 77.16), benzene (δ 
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128.06) or methanol (δ 49.15) for 13C spectra. The following abbreviations are used to 
describe multiplicities in 1H NMR spectra: s (singlet), brs (broad singlet), d (doublet), dd 
(doublet of doublets), ddd (doublet of doublet of doublets), dt (doublet of triplets), dq 
(doublet of quartets), t (triplet), td (triplet of doublets), m (multiplet) and q (quartet), app 
(apparent). High-resolution mass spectra (HRMS) were measured on a LC-TOF mass 
spectrometer. 
 
 
3.1.2 Experimental Procedures 
 
 
Alcohol (+)-1.10: To glycidol benzyl ether (600 mg, 3.65 mmol, 1.0 equiv., prepared 
according to literature procedure1) in THF (36.5 ml, 0.1 M) at -20 oC, CuI (696 mg, 3.65 
mmol, 1.0 equiv.) wad added. Next vinyl magnesium bromide (1 M in THF, 9.14 ml, 
9.14 mmol, 2.5 equiv.) was added quickly to the suspension. After stirring for 2 hours at 
the same temperature, the reaction was quenched by saturated aqueous NH4Cl solution. 
The organic layer was separated, and the aqueous layer was extracted with DCM. The 
combined organic layers were washed with brine, dried over MgSO4, and filtered. The 
filtrate was concentrated in vacuo to provide the crude product as yellow oil, which was 
used directly for next step without purification. 
 
OBnHO
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Alkene (+)-1.11: To crude alcohol (+)-1.10 (1 g, 5.2 mmol, 1.0 equiv.) in DCM (52 ml, 
0.1 M), DMAP (63.5 mg, 0.52 mmol, 0.1 equiv.), imidazole (1.77 g, 26 mmol, 5.0 
equiv.) and TBSCl (3.92 g, 26 mmol, 5.0 equiv.) were added at room temperature. The 
reaction mixture was stirred overnight before it was quenched by saturated aqueous 
NH4Cl solution. The organic layer was separated, and the aqueous layer was extracted 
with DCM. The combined organic layers were washed with brine, dried over MgSO4, and 
filtered. The filtrate was concentrated in vacuo to provide the crude product as brown oil. 
This oil was then purified with silica gel flash column chromatography (19:1 
hexane/EtOAc) to afford the title compound (1.43 g, 90%) as colorless oil. The 1H NMR 
and 13C NMR of the title compound matched with the literature report.2 
 
 
Epoxide 1.12: To homoallylic alcohol (+)-1.11 (500 mg, 1.63 mmol, 1.0 equiv.) in DCM 
(11 ml, 0.15 M), m-CPBA (731.2 mg, 3.26 mmol, 2.0 equiv.) was added portionwise at 0 
oC. The reaction then warmed up to room temperature and stirred for overnight. Upon 
completion, the mixture was quenched by saturated aqueous NaHCO3 solution. The 
organic layer was separated, and the aqueous layer was extracted with DCM. The 
combined organic layers were washed with brine, dried over MgSO4, and filtered. The 
OBnTBSO
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filtrate was concentrated in vacuo to provide the crude product as brown oil. This oil was 
then purified with silica gel flash column chromatography (19:1 hexane/EtOAc) to afford 
the title compound (473 mg, 90%) as colorless oil. IR (film) 2927.41 2855.1 1471.9 
1253.5 1110.8 836.473 776.208 734.746 697.623 666.767 cm-1; 1H NMR (500 MHz, 
Chloroform-d) δ 7.39 – 7.26 (m, 5H), 4.59 – 4.53 (m, 2H), 4.08 (dp, J = 11.3, 5.7 Hz, 
1H), 3.58 – 3.39 (m, 2H), 3.13 – 3.02 (m, 1H), 2.79 (ddd, J = 21.4, 5.2, 4.0 Hz, 1H), 2.50 
(ddd, J = 14.8, 5.2, 2.7 Hz, 1H), 1.76 (dt, J = 25.2, 5.9 Hz, 2H), 0.92 (d, J = 1.6 Hz, 9H), 
0.14 – 0.08 (m, 6H); 13C NMR (126 MHz, Chloroform-d) δ 138.45, 138.38, 128.48, 
127.77, 127.75, 127.72, 127.70, 74.78, 74.47, 73.53, 73.45, 69.86, 69.45, 49.75, 49.50, 
47.93, 46.91, 38.22, 38.08, 25.99, 25.97, 18.25, -4.25, -4.31, -4.77, -4.79; HRMS (ESI) 
m/z 345.1895 [(M+Na)+; calcd for C18H30O3SiNa: 345.1862]. 
 
 
Epoxide (-)-1.13: Epoxide 1.12 (250 mg, 0.78 mmol, 1.0 equiv.) in THF (0.05 ml + 0.05 
ml) was added to (S,S)-Jacobsen’s catalyst (603 mg, 0.016 mmol, 2.2% equiv., the 
catalyst was pre-activated according to literature procedure3) at 0 oC and stirred for 5 
min. Then H2O (7.7 μl, 0.43 mmol, 0.55 equiv.) was added, and the reaction mixture was 
warmed up to room temperature. The reaction was monitored by 1H NMR. After the 
reaction was completed (about 60 hours), the mixture was concentrated in vacuo to 
provide the crude product as brown oil. This oil was then purified with silica gel flash 
column chromatography (19:1 hexane/EtOAc) to afford the title compound (145 mg, 
OBnTBSO
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58%) as colorless oil. [a]D 22 = – 52.0 (c 1.0, CH2Cl2); IR (film) 2927.41 2856.06 
1683.07 1652.21 1557.72 1471.42 1255.91 1109.83 834.544 777.654 cm-1; 1H NMR (500 
MHz, Chloroform-d) δ 7.38 – 7.29 (m, 5H), 4.54 (d, J = 3.0 Hz, 2H), 4.08 (dq, J = 7.4, 
5.4 Hz, 1H), 3.43 (qd, J = 9.6, 5.6 Hz, 2H), 3.06 (dddd, J = 6.5, 5.6, 3.9, 2.7 Hz, 1H), 2.80 
(dd, J = 5.1, 4.0 Hz, 1H), 2.51 (dd, J = 5.1, 2.7 Hz, 1H), 1.73 (ddd, J = 7.3, 5.0, 3.2 Hz, 
2H), 0.91 (s, 9H), 0.10 (d, J = 8.7 Hz, 6H); 13C NMR (126 MHz, Chloroform-d) δ 138.37, 
128.47, 127.74, 127.70, 74.77, 73.45, 69.43, 49.75, 47.93, 38.21, 25.96, 18.23, -4.28, -
4.81; HRMS (ESI) m/z 323.2045 [(M+H)+; calcd for C18H31O3Si: 345.2042]. 
 
 
Lactone (-)-1.14: To anhydrous ethanol (26 ml, 0.13 M) at 0 oC, NaH (546 mg, 13.64 
mmol, 4 equiv., 60% in mineral oil) was added portionwise (gas generated). The mixture 
was then warmed up to room temperature and stirred for 5 min. Diethyl malonate (2.18 g, 
13.64 mmol, 4 equiv.) was added to above suspension dropwise resulting white cloudy 
mixture. After stirred for 30 min, epoxide (-)-1.13 (1.1 g, 3.4 mmol, 1.0 equiv.) was 
added dropwise. After refluxed for 3 hours, the reaction mixture was cooled to room 
temperature and was quenched by saturated aqueous NH4Cl solution. The organic layer 
was separated, and the aqueous layer was extracted with DCM. The combined organic 
layers were washed with brine, dried over MgSO4, and filtered. The filtrate was 
concentrated in vacuo to provide the crude product as orange-red oil. This oil was then 
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purified with silica gel flash column chromatography (9:1 hexane/EtOAc) to afford the 
title compound (1.24 g, 84%) as colorless oil. [a]D 22 = – 42.7 (c 1.0, CH2Cl2); IR (film) 
2930.31 1780.94 1737.07 1472.87 1370.18 1253.99 1163.35 836.473 776.69 697.623 cm-
1; 1H NMR (500 MHz, Chloroform-d) δ 7.39 – 7.31 (m, 5H), 4.92 (dtd, J = 10.2, 7.1, 3.1 
Hz, 1H), 4.69 (tdd, J = 9.5, 6.2, 3.0 Hz, 1H), 4.30 – 4.22 (m, 2H), 4.09 (dp, J = 12.5, 4.4, 
3.7 Hz, 1H), 3.69 – 3.57 (m, 1H), 3.48 – 3.33 (m, 2H), 2.72 (ddd, J = 13.1, 6.9, 4.9 Hz, 
1H), 2.59 (ddd, J = 12.9, 9.3, 6.2 Hz, 0H), 2.36 (ddd, J = 13.0, 10.9, 9.3 Hz, 0H), 2.15 
(ddd, J = 13.2, 9.5, 7.3 Hz, 0H), 2.01 (ddd, J = 14.5, 9.9, 2.8 Hz, 0H), 1.93 – 1.73 (m, 
1H), 1.33 (td, J = 7.1, 2.9 Hz, 3H), 0.90 (d, J = 3.8 Hz, 9H), 0.13 – 0.05 (m, 6H); 13C 
NMR (126 MHz, Chloroform-d) δ 171.84 (d, J = 15.3 Hz), 167.96, 138.23, 128.51, 
127.78, 76.98, 76.16, 74.73, 74.70, 73.48, 73.47, 68.22, 68.16, 62.34, 62.26, 47.57, 47.24, 
41.11, 41.03, 32.77, 32.64, 26.01, 25.99, 18.23, 18.21, 14.20, -4.20, -4.26, -4.75, -4.78; 
HRMS (ESI) m/z 459.2190 [(M+Na)+; calcd for C23H36O6SiNa: 459.2179]. 
 
 
Alcohol (-)-1.15: A solution of malonate (-)-1.14 (200 mg, 0.46 mmol, 1.0 equiv.) and 
LiCl (38.8 mg, 0.92 mmol, 2.0 equiv.) in DMSO (2.5 ml, 0.18 M) and H2O (0.03 ml, 1.6 
mmol, 3.5 equiv.) was heated and refluxed at 155 oC for 5 hours. The reaction mixture 
was cooled to room temperature and was quenched by saturated aqueous NH4Cl solution. 
The organic layer was separated, and the aqueous layer was extracted with DCM. The 
OBnHO
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combined organic layers were washed with brine, dried over MgSO4, and filtered. The 
filtrate was concentrated in vacuo to provide the crude product as brown oil. This oil was 
then purified with silica gel flash column chromatography (2:3 hexane/EtOAc) to afford 
the title compound (112 mg, 93%) as colorless oil. [a]D 22 = – 36.8 (c 1.0, CH2Cl2); IR 
(film) 3852.11 3445.69 2864.74 1770.811558.2 1455.51 1361.98 1183.6 1091.03 
916.504 cm-1; 1H NMR (500 MHz, Chloroform-d) δ 7.41 – 7.28 (m, 5H), 4.79 (tdd, J = 
8.5, 6.5, 4.0 Hz, 1H), 4.56 (d, J = 1.2 Hz, 2H), 4.08 (dp, J = 10.6, 3.4 Hz, 1H), 3.54 (dd, J 
= 9.5, 3.3 Hz, 1H), 3.36 (dd, J = 9.5, 7.3 Hz, 1H), 2.58 – 2.50 (m, 2H), 2.43 – 2.31 (m, 
1H), 1.89 (dtd, J = 12.8, 9.5, 8.3 Hz, 1H), 1.82 – 1.68 (m, 2H); 13C NMR (126 MHz, 
Chloroform-d) δ 177.21, 137.88, 128.64, 128.03, 127.89, 78.01, 74.44, 73.48, 67.47, 
39.48, 29.02, 28.69; HRMS (CI) m/z 251.1284 [(M+Na)+; calcd for C14H20O4: 251.1283]. 
 
 
Lactone (-)-1.26: To alcohol (-)-1.15 (112 mg, 0.045 mmol, 1.0 equiv.) in DCM (4.5 
ml, 1.0 M) at room temperature, 2, 6-lutidine (0.16 ml, 1.34 mmol, 3.0 equiv.) was added 
followed by dropwise addition of TBSOTf (0.2 ml, 0.89 mmol, 2.0 equiv.). The light-
yellow solution was stirred for 1 h and then was quenched by saturated aqueous NH4Cl 
solution. The organic layer was separated, and the aqueous layer was extracted with 
DCM. The combined organic layers were washed with brine, dried over MgSO4, and 
filtered. The filtrate was concentrated in vacuo to provide the crude product as yellow oil. 
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This oil was then purified with silica gel flash column chromatography (9:1 
hexane/EtOAc) to afford the title compound (138.7 mg, 85%) as colorless oil. [a]D 22 = – 
52.0 (c 1.0, CH2Cl2); IR (film) 2928.38 2855.58 1778.53 1471.9 1361.98 1252.54 1180.7 
1096.82 914.575 836.473 cm-1; 1H NMR (500 MHz, Chloroform-d) δ 7.39 – 7.28 (m, 
5H), 4.72 (dtd, J = 10.1, 7.5, 3.1 Hz, 1H), 4.53 (d, J = 1.7 Hz, 2H), 4.08 (dtd, J = 10.0, 
5.2, 2.7 Hz, 1H), 3.44 (dd, J = 9.7, 4.9 Hz, 1H), 3.37 (dd, J = 9.6, 5.6 Hz, 1H), 2.55 (dd, J 
= 9.4, 7.1 Hz, 2H), 2.40 – 2.32 (m, 1H), 1.94 – 1.84 (m, 2H), 1.76 (ddd, J = 14.2, 9.8, 3.0 
Hz, 1H), 0.89 (s, 9H), 0.08 (d, J = 12.2 Hz, 6H); 13C NMR (126 MHz, Chloroform-d) δ 
177.27, 138.27, 128.49, 127.76, 77.55, 74.79, 73.44, 68.23, 41.26, 28.95, 28.53, 26.01, 
18.23, -4.23, -4.74; HRMS (ESI) m/z 364.2148 [(M+H)+; calcd for C20H34O4Si: 
364.2148]. 
 
 
Alcohol (-)-1.16: To lactone (-)-1.26 (290 mg, 0.795 mmol, 1.0 equiv.) in THF/MeOH 
(7.5 ml/7.5 ml, 0.05 M), Palladium on carbon (58 mg, 20% weight) was added in one 
portion at room temperature. Then the reaction mixture was purged by hydrogen gas 
three times. After stirred for 1 hour, the mixture was filtered via a pad of Celite and 
washed by EtOAc. The filtrated was concentrated in vacuo to provide the crude product 
as light-yellow oil. This oil was then purified with silica gel flash column 
chromatography (3:2 hexane/EtOAc) to afford the title compound (207.4 mg, 95%) as 
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colorless oil. [a]D 22 = – 68.0 (c 1.0, CH2Cl2); IR (film) 3480.4 2929.34 92.5344 3 
2857.02 1771.3 1471.9 1252.54 1183.11 1061.62 836.955 777.172 cm-1; 1H NMR (500 
MHz, Chloroform-d) δ 4.64 (dtd, J = 10.0, 7.3, 2.8 Hz, 1H), 4.00 (dq, J = 9.8, 3.6 Hz, 
1H), 3.62 (dd, J = 11.3, 4.2 Hz, 1H), 3.47 (dd, J = 11.3, 3.5 Hz, 1H), 2.57 – 2.52 (m, 2H), 
2.37 (dq, J = 13.2, 6.8 Hz, 1H), 1.94 – 1.85 (m, 3H), 1.76 (ddd, J = 14.6, 10.1, 3.2 Hz, 
1H), 0.91 (s, 9H), 0.11 (d, J = 1.9 Hz, 6H); 13C NMR (126 MHz, Chloroform-d) δ 177.16, 
77.64, 69.52, 66.90, 40.59, 28.90, 28.52, 25.95, 18.16, -4.36, -4.63; HRMS (ESI) m/z 
275.1679 [(M+H)+; calcd for C13H28O4Si: 275.1674]. 
 
 
Aldehyde (-)-1.3: To oxalyl chloride (0.19 ml, 2.22 mmol, 2.0 equiv.) in DCM (15 ml) 
at -78 oC, DMSO (0.39 ml, 5.55 mmol, 5.0 equiv.) was added dropwise. After stirred at 
this temperature for 30 min, alcohol (-)-1.16 (305 mg, 1.11 mmol, 1.0 equiv.) in DCM 
(11 ml) was added dropwise. After stirred for 20 min, triethyl amine (0.62 ml, 4.44 
mmol, 4.0 equiv.) was added dropwise followed by warming up to room temperature in 1 
hour. The reaction mixture was then quenched by water. The organic layer was separated, 
and the aqueous layer was extracted with DCM. The combined organic layers were 
washed with brine, dried over MgSO4, and filtered. The filtrate was concentrated in 
vacuo to provide the crude product as yellow oil. This oil was then purified with silica gel 
flash column chromatography (7:3 hexane/EtOAc) to afford the title compound (242 mg, 
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80%) as pale-yellow oil. [a]D 22 = – 64.2 (c 1.0, CH2Cl2); IR (film) 2929.34 2856.54 
1778.53 1738.03 1471.9 1254.47 1179.74 913.129 837.919 779.583 cm-1; 1H NMR (500 
MHz, Chloroform-d) δ 9.62 (d, J = 1.0 Hz, 1H), 4.68 (dtd, J = 9.9, 7.1, 3.0 Hz, 1H), 4.26 
(dd, J = 10.3, 3.0 Hz, 1H), 2.56 (dd, J = 9.3, 6.7 Hz, 2H), 2.38 (ddt, J = 13.5, 7.6, 6.7 Hz, 
1H), 2.00 (ddd, J = 14.3, 10.0, 3.0 Hz, 1H), 1.96 – 1.86 (m, 1H), 1.77 (ddd, J = 14.3, 
10.2, 3.1 Hz, 1H), 0.92 (s, 9H), 0.10 (d, J = 5.7 Hz, 6H); 13C NMR (126 MHz, 
Chloroform-d) δ 202.91, 176.68, 76.18, 74.74, 38.39, 28.73, 28.19, 25.85, 18.25, -4.46, -
4.99; HRMS (ESI) m/z 273.1522 [(M+H)+; calcd for C13H25O4Si: 273.1522]. 
 
 
Lactone (-)-1.27: To alcohol (-)-1.15 (100 mg, 0.4 mmol, 1.0 equiv.) at room 
temperature, silver oxide (140 mg, 0.6 mmol, 1.5 equiv.), molecular sieves powder (100 
mg, flamed dried) and methyl iodide (2 ml, 0.2 M) was added. The reaction mixture was 
stirred for 24 hours in the dark before it was filtered via a pad of celite. The filtrate was 
concentrated in vacuo to provide the crude product as a yellow oil. This oil was then 
purified with silica gel flash column chromatography (3:2 hexane/EtOAc) to afford the 
title compound (95 mg, 90%) as pale-yellow oil. [a]D 22 = – 63.4 (c 1.0, CH2Cl2); IR 
(film) 3853.56 3745.56 2917.29 1772.74 1456.96 1179.26 749.692 698.105 676.41 
623.377 cm-1; 1H NMR (500 MHz, Chloroform-d) δ 7.40 – 7.26 (m, 5H), 4.80 – 4.71 (m, 
1H), 4.56 (d, J = 3.2 Hz, 2H), 3.64 – 3.45 (m, 3H), 3.44 (s, 3H), 2.58 – 2.51 (m, 2H), 2.35 
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(dq, J = 13.0, 6.7 Hz, 1H), 1.94 – 1.75 (m, 3H); 13C NMR (126 MHz, Chloroform-d) δ 
177.30, 138.21, 128.54, 127.82, 127.75, 77.98, 73.51, 71.20, 58.19, 38.91, 29.05, 28.54; 
HRMS (ESI) m/z 264.1396 [M+; calcd for C15H20O4: 264.1362]. 
 
 
Alcohol (-)-1.28: To lactone (-)-1.27 (90 mg, 0.34 mmol, 1.0 equiv.) in THF/MeOH (3.3 
ml/3.3 ml, 0.05 M), Palladium on carbon (18 mg, 20% weight) was added in one portion 
at room temperature. Then the reaction mixture was purged by hydrogen gas three times. 
After stirred for 1 hour, the mixture was filtered via a pad of celite and washed by 
EtOAc. The filtrated was concentrated in vacuo to provide the crude product as light-
yellow oil. This oil was then purified with silica gel flash column chromatography (1:4 
hexane/EtOAc) to afford the title compound (54 mg, 91%) as colorless oil. [a]D 22 = – 
67.2 (c 2.0, CH2Cl2); IR (film) 3852.11 3446.17 2941.39 1770.81 1652.7 1558.2 1456.96 
1186.97 1074.64 918.915 cm-1; 1H NMR (500 MHz, Chloroform-d) δ 4.72 (dddd, J = 9.8, 
8.4, 6.6, 3.0 Hz, 1H), 3.84 (dd, J = 11.6, 3.5 Hz, 1H), 3.54 – 3.45 (m, 2H), 3.45 (s, 3H), 
2.58 – 2.53 (m, 2H), 2.37 (td, J = 13.2, 12.5, 6.6 Hz, 1H), 1.96 – 1.84 (m, 2H), 1.74 (ddd, 
J = 14.7, 10.0, 3.2 Hz, 1H); 13C NMR (126 MHz, Chloroform-d) δ 177.26, 78.19, 78.01, 
63.20, 57.98, 38.24, 29.00, 28.57; HRMS (ESI) m/z 197.0798 [(M+Na)+; calcd for 
C8H14O4Na: 197.0790]. 
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Aldehyde (-)-1.17: To oxalyl chloride (0.053 ml, 0.62 mmol, 2.0 equiv.) in DCM (3 ml) 
at -78 oC, DMSO (0.11 ml, 1.55 mmol, 5.0 equiv.) was added dropwise. After stirred at 
this temperature for 30 min, alcohol (-)-1.28 (54 mg, 0.31 mmol, 1.0 equiv.) in DCM (2 
ml) was added dropwise. After stirred for 20 min, triethyl amine (0.17 ml, 1.24 mmol, 4.0 
equiv.) was added dropwise followed by warming up to room temperature in 1 hour. The 
reaction mixture was then quenched by water. The organic layer was separated, and the 
aqueous layer was extracted with DCM. The combined organic layers were washed with 
brine, dried over MgSO4, and filtered. The filtrate was concentrated in vacuo to provide 
the crude product as yellow oil. This oil was then purified with silica gel flash column 
chromatography (2:3 hexane/EtOAc) to afford the title compound (42.7 mg, 80%) as 
pale-yellow oil. 1H NMR (500 MHz, Chloroform-d) δ 9.68 (s, 1H), 4.72 (dddd, J = 10.2, 
8.7, 6.7, 3.3 Hz, 1H), 3.85 (ddd, J = 10.5, 3.0, 1.4 Hz, 1H), 3.50 (s, 3H), 2.59 – 2.53 (m, 
2H), 2.38 (dq, J = 13.2, 6.8 Hz, 1H), 1.99 (ddd, J = 13.1, 9.8, 3.1 Hz, 1H), 1.95 – 1.85 (m, 
1H), 1.79 (ddd, J = 14.0, 10.5, 3.4 Hz, 1H); 13C NMR (126 MHz, Chloroform-d) δ 
202.54, 176.75, 82.61, 76.53, 76.47, 59.16, 36.11, 28.83, 28.26. 
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PMB Ether (+)-1.23: To Wittig salt fragment 1.4 (130 mg, 0.12 mmol, 1.0 equiv., 
prepared according to literature4) in THF (2 ml), MeLi.LiBr (0.08 ml, 1.5 M in Et2O, 0.12 
mmol, 1.0 equiv.) was added at room temperature. The mixture was stirred for 5 min 
before it was cool to -78 oC. After stirring for 20 mins, aldehyde (-)-1.3 (32.5 mg, 0.12 
mmol, 1.0 equiv.) in THF (2 ml) was added dropwise. The reaction was then allowed to 
warm up to room temperature naturally overnight. The reaction mixture was then 
quenched by saturated aqueous NH4Cl solution. The organic layer was separated, and the 
aqueous layer was extracted with EtOAc. The combined organic layers were washed with 
brine, dried over MgSO4, and filtered. The filtrate was concentrated in vacuo to provide 
the crude product as yellow oil. This oil was then purified with silica gel flash column 
chromatography (4:1 hexane/EtOAc) to afford the title compound (33 mg, 30 %) as 
yellow oil. [a]D 22 = + 28.7 (c 1.0, CH2Cl2); IR (film) 2928.86 2856.54 1782.39 1514.33 
1462.26 1249.65 1042.34 835.99 774.279 cm-1; 1H NMR (500 MHz, Chloroform-d) δ 
7.29 (d, J = 8.6 Hz, 2H), 6.88 (d, J = 8.7 Hz, 2H), 6.65 – 6.54 (m, 1H), 6.02 (t, J = 11.0 
Hz, 1H), 5.58 (t, J = 10.5 Hz, 1H), 5.27 – 5.19 (m, 3H), 5.13 (d, J = 10.0 Hz, 1H), 4.99 (d, 
J = 10.0 Hz, 1H), 4.71 (dq, J = 8.2, 6.7 Hz, 1H), 4.65 – 4.60 (m, 1H), 4.57 (d, J = 10.5 Hz, 
1H), 4.47 (d, J = 10.5 Hz, 1H), 3.81 (s, 3H), 3.44 (dd, J = 5.4, 3.4 Hz, 1H), 3.26 (dd, J = 
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7.7, 3.7 Hz, 1H), 3.22 (t, J = 5.4 Hz, 1H), 3.01 (ddd, J = 10.4, 6.9, 3.6 Hz, 1H), 2.59 – 
2.48 (m, 3H), 2.43 (dt, J = 10.1, 6.3 Hz, 1H), 2.35 – 2.26 (m, 1H), 2.00 (t, J = 12.4 Hz, 
1H), 1.85 – 1.79 (m, 2H), 1.78 – 1.74 (m, 1H), 1.72 (td, J = 6.4, 5.5, 2.6 Hz, 2H), 1.64 (d, 
J = 12.8 Hz, 1H), 1.55 (d, J = 1.3 Hz, 3H), 1.12 (d, J = 6.8 Hz, 3H), 1.01 (d, J = 6.8 Hz, 
3H), 0.96 (d, J = 3.2 Hz, 12H), 0.92 (s, 9H), 0.89 (s, 9H), 0.87 (d, J = 6.6 Hz, 3H), 0.72 
(d, J = 6.7 Hz, 3H), 0.11 (d, J = 4.2 Hz, 6H), 0.08 (d, J = 1.6 Hz, 6H), 0.05 (s, 3H), 0.03 
(s, 3H); 13C NMR (126 MHz, Chloroform-d) δ 177.09, 159.16, 134.49, 132.94, 132.83, 
132.29, 131.70, 129.30, 129.18, 117.80, 113.81, 84.71, 80.62, 77.58, 75.21, 66.04, 55.41, 
44.91, 40.19, 37.83, 36.08, 35.44, 29.01, 28.44, 26.44, 26.34, 26.00, 23.10, 18.82, 18.76, 
18.54, 18.27, 17.03, 15.05, 10.62, -2.99, -3.02, -3.13, -4.07, -4.17, -4.67; HRMS (ESI) 
m/z 977.6590 [(M+H)+; calcd for C55H98NaO7Si3: 977.6518]. 
 
 
Alcohol (+)-1.24: To PMB ether (+)-1.23 (30 mg, 0.031 mmol, 1.0 equiv.) in 
DCM/H2O (0.015 M, 2 ml/0.07 ml), DDQ (10.7 mg, 0.047 mmol, 1.5 equiv.) was added 
at 0 oC. After stirring for 15 mins at the same temperature, the reaction was warmed up to 
room temperature and was stirred for another 1 hour. The reaction mixture was then 
quenched by saturated aqueous NaHCO3 solution. The organic layer was separated, and 
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the aqueous layer was extracted with EtOAc. The combined organic layers were washed 
with brine, dried over MgSO4, and filtered. The filtrate was concentrated in vacuo to 
provide the crude product as yellow oil. This oil was then purified with silica gel flash 
column chromatography (9:1 hexane/EtOAc) to afford the title compound (24 mg, 89 %) 
as yellow oil. [a]D 22 = + 45.0 (c 1.0, CH2Cl2) IR (film) 2925.97 2853.65 1779.97 1558.2 
1456.47 1252.06 1087.17 836.473 774.279 cm-1; 1H NMR (500 MHz, Chloroform-d) δ 
6.64 (dddd, J = 16.8, 11.2, 10.2, 1.1 Hz, 1H), 6.20 – 6.11 (m, 1H), 5.35 (t, J = 10.5 Hz, 
1H), 5.29 – 5.23 (m, 3H), 5.17 (d, J = 9.9 Hz, 1H), 5.05 (d, J = 9.8 Hz, 1H), 4.76 – 4.68 
(m, 1H), 4.64 (q, J = 6.5 Hz, 1H), 3.63 (dd, J = 5.7, 3.3 Hz, 1H), 3.35 (dt, J = 7.9, 3.0 Hz, 
1H), 3.26 (t, J = 5.3 Hz, 1H), 2.82 (dt, J = 10.0, 7.0 Hz, 1H), 2.59 – 2.46 (m, 4H), 2.34 
(dddd, J = 12.8, 8.7, 6.7, 5.2 Hz, 1H), 2.20 (t, J = 12.4 Hz, 1H), 1.93 – 1.80 (m, 3H), 1.77 
– 1.71 (m, 3H), 1.60 (s, 3H), 1.00 – 0.95 (m, 9H), 0.94 (s, 9H), 0.92 (s, 9H), 0.90 (d, J = 
6.7 Hz, 3H), 0.89 (s, 9H), 0.75 (d, J = 6.8 Hz, 3H), 0.10 (d, J = 1.9 Hz, 6H), 0.07 (d, J = 
4.9 Hz, 6H), 0.05 (d, J = 8.1 Hz, 6H); 13C NMR (126 MHz, Chloroform-d) δ 177.13, 
134.79, 132.98, 132.85, 132.19, 131.86, 131.74, 131.17, 118.62, 80.65, 78.88, 77.62, 
76.41, 66.11, 44.88, 38.11, 37.65, 36.41, 35.55, 34.95, 29.84, 29.01, 28.44, 26.37, 26.00, 
23.31, 18.61, 18.57, 18.26, 17.31, 17.25, 16.78, 13.65, 9.61, -2.90, -3.14, -3.43, -4.07, -
4.14, -4.68; 13C NMR (126 MHz, Chloroform-d) δ 177.21, 157.24, 129.96, 118.13, 80.64, 
78.92, 77.64, 76.94, 66.07, 44.86, 37.97, 37.74, 36.32, 35.56, 35.21, 34.55, 29.84, 29.01, 
28.40, 26.35, 25.99, 23.06, 18.65, 18.55, 18.26, 17.62, 17.13, 17.00, 13.70, 10.25, -2.96, -
3.24, -3.34, -4.08, -4.15, -4.67. 
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Carbamate 1.25: To alcohol (+)-1.24 (22 mg, 0.026 mmol, 1.0 equiv.) in DCM (2 ml), 
trichloroacetyl isocyanate (0.08 ml, 1 M in DCM, 0.08 mmol, 3.0 equiv.) was added 
dropwise at room temperature. After stirring for 2 hours, the mixture was loaded on a 
column with Al2O3 (pre-wash by DCM) followed by a 2 ml DCM rinse. After 4 hours, 
the crude was flushed by EtOAc (80 ml) and MeOH (30 ml). Concentration and 
purification with silica gel flash column chromatography (4:1 hexane/EtOAc) to afford 
the title compound (22 mg, 90 %) as yellow oil. 1H NMR (500 MHz, Chloroform-d) δ 
6.65 – 6.56 (m, 2H), 6.33 – 6.2 (br, 2H), 6.04 (t, J = 11.0 Hz, 1H), 5.38 (t, J = 10.5 Hz, 
1H), 5.28 – 5.21 (m, 3H), 5.17 – 5.12 (m, 1H), 5.02 (d, J = 10.3 Hz, 1H), 4.75 – 4.66 (m, 
3H), 4.66 – 4.62 (m, 3H), 3.45 – 3.41 (m, 1H), 3.24 (t, J = 5.4 Hz, 1H), 3.00 (dt, J = 10.2, 
6.7 Hz, 1H), 2.57 – 2.51 (m, 3H), 2.46 (dt, J = 10.0, 6.4 Hz, 1H), 2.38 – 2.30 (m, 1H), 
2.12 (t, J = 12.3 Hz, 1H), 1.94 – 1.82 (m, 4H), 1.74 – 1.65 (m, 4H), 1.26 (s, 3H), 1.01 (d, 
J = 6.8 Hz, 3H), 0.97 (d, J = 6.8 Hz, 3H), 0.94 (d, J = 1.9 Hz, 12H), 0.92 (s, 9H), 0.88 (s, 
12H), 0.72 (d, J = 6.8 Hz, 3H), 0.10 (d, J = 12.0 Hz, 6H), 0.07 (d, J = 3.3 Hz, 6H), 0.04 
(d, J = 9.3 Hz, 6H); 13C NMR (126 MHz, Chloroform-d) δ 177.21, 157.24, 129.96, 
118.13, 80.64, 78.92, 77.64, 66.07, 44.86, 37.97, 37.74, 36.32, 35.56, 35.21, 34.55, 29.84, 
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29.01, 28.40, 26.35, 25.99, 23.06, 18.65, 18.55, 18.26, 17.62, 17.13, 17.00, 13.70, 10.25, 
-2.96, -3.24, -3.34, -4.08, -4.15, -4.67. 
 
 
Butyrolactone 1.2: To carbamate 1.25 (15 mg, 0.017 mmol) in MeOH (4.5 ml), 4 N HCl 
(1.2 ml) was added dropwise in 2 hours. White precipitation was observed. The reaction 
was stirred at room temperature overnight before it was quenched by saturated aqueous 
NaHCO3 solution. The organic layer was separated, and the aqueous layer was extracted 
with EtOAc. The combined organic layers were washed with brine, dried over MgSO4, 
and filtered. The filtrate was concentrated in vacuo to provide the crude product as brown 
oil. This oil was then purified with silica gel flash column chromatography (3% 
MeOH/DCM to 4.5% MeOH/DCM) to afford the title compound (10 mg, 50%) as 
colorless oil. 1H NMR (500 MHz, Chloroform-d) δ 6.63 (dt, J = 16.7, 10.6 Hz, 1H), 6.04 
(t, J = 11.0 Hz, 1H), 5.55 – 5.44 (m, 2H), 5.38 (t, J = 10.5 Hz, 1H), 5.24 (d, J = 16.7 Hz, 
1H), 5.19 – 5.11 (m, 2H), 4.82 – 4.59 (m, 5H), 3.29 (t, J = 5.3 Hz, 1H), 3.22 (dd, J = 6.6, 
4.9 Hz, 1H), 3.02 (dt, J = 10.1, 6.8 Hz, 1H), 2.80 (dt, J = 9.3, 6.7 Hz, 1H), 2.59 – 2.52 
(m, 2H), 2.39 (dq, J = 13.2, 6.6 Hz, 1H), 2.06(m, 2H), 1.98 – 1.79 (m, 6H), 1.67 (d, J = 
O OH
O
O
OH
HO
O
NH2
 78 
1.3 Hz, 3H), 1.04 (d, J = 6.8 Hz, 3H), 1.03 – 0.98 (m, 6H), 0.96 (d, J = 6.8 Hz, 3H), 0.84 
(d, J = 6.1 Hz, 3H); 13C NMR (126 MHz, Chloroform-d) δ 177.19, 157.19, 134.90, 
133.81, 133.79, 132.71, 132.26, 130.03, 129.67, 118.07, 79.06, 78.88, 78.09, 75.99, 
65.55, 43.35, 37.48, 36.06, 35.95, 35.33, 34.85, 33.19, 28.98, 28.63, 23.42, 18.59, 17.59, 
15.69, 13.89, 9.01; HRMS (ESI) m/z 558.3387 [(M+Na)+; calcd for C30H49NO7Na: 
558.3407]. The 1H NMR and 13C NMR of the title compound matched with the literature 
report.5 
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3.2 Experimental Section Relevant to Chapter Two 
 
3.2.1 Materials and Methods 
Reactions were performed either in flame or oven-dried glassware under a nitrogen 
atmosphere unless noted otherwise. Anhydrous diethyl ether (Et2O), tetrahydrofuran 
(THF), dichloromethane (CH2Cl2) and toluene were obtained from a solvent purification 
system. Triethylamine, diisopropylethylamine and pyridine were freshly distilled from 
calcium hydride under a nitrogen atmosphere. All chemicals were purchased from 
commercial vendors, unless otherwise referenced. Reactions were magnetically stirred 
unless stated otherwise and monitored by thin layer chromatography (TLC) with 0.25 
mm pre-coated silica gel plates. Silica gel chromatography was performed utilizing ACS 
grade solvents and silica gel. Preparatory TLC was performed using 500 μm pre-coated 
silica gel plates and ACS grade solvents. Medium pressure liquid chromatography was 
conducted by using a medium pressure pump equipped with a high pressure glass column 
(350 mm ÅL 35 mm or 350 mm Å~ 10 mm) packed with silica gel (Standard Grade, 
porosity 60 Å, particle size 32-63 μm). Infrared spectra were obtained using a FT/IR plus 
spectrometer. Optical rotations were obtained using a polarimeter at 589 nm. CD spectra 
were obtained using a circular dichroism spectrometer in a 1 mm quartz cell. 1H NMR 
spectra (500 MHz field strength) and 13C NMR spectra (125 MHz field strength) were 
obtained on a 500 MHz spectrometer or a cryomagnet (500MHz/52mm) with a 5 mm 
dual cryoprobe. Chemical shifts are reported relative to chloroform (δ 7.26), benzene (δ 
7.16) or methanol (δ 3.31) for 1H NMR spectra and chloroform (δ 77.16), benzene (δ 
128.06) or methanol (δ 49.15) for 13C spectra. The following abbreviations are used to 
describe multiplicities in 1H NMR spectra: s (singlet), brs (broad singlet), d (doublet), dd 
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(doublet of doublets), ddd (doublet of doublet of doublets), dt (doublet of triplets), dq 
(doublet of quartets), t (triplet), td (triplet of doublets), m (multiplet) and q (quartet), app 
(apparent). High-resolution mass spectra (HRMS) were measured on a LC-TOF mass 
spectrometer. 
 
3.2.2 Experimental Procedures 
 
 
Aldehyde 2.14: To 2-(tert-butyldimethylsilyloxy) ethanol (8 g, 45.37 mmol) in DCM 
(181.5 ml, 0.25 M), KBr (540 mg, 4.5 mmol, 0.1 equiv.) in H2O (4.5 ml, 1 M) was added. 
The solution was then cooled to 0 oC, TEMPO (14.4 mg, 0.2 % equiv.) and saturated 
NaHCO3 (136.45 ml) aqueous solution were added. Bleach (NaClO 8.25% wt) was then 
added slowly via dropping funnel. Upon completion the color of the reaction turned from 
light orange to colorless. Next saturated Na2S2O3 aqueous solution was added via 
dropping funnel, and the reaction was warmed up to room temperature naturally. The 
organic layer was separated, and the aqueous layer was extracted with Et2O. The 
combined organic layers were washed with brine, dried over MgSO4, and filtered. The 
filtrate was concentrated in vacuo (room temperature water bath) to provide the crude 
product as light-yellow oil. This oil was then purified with silica gel flash column 
chromatography (pentane) to afford the title compound (7.49 g, 94.9%) as colorless oil. 
(Caution: the compound is volatile and unstable upon long-term storage) The 1H NMR 
and 13C NMR of the title compound matched with the literature report.1 
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Alcohol (–)-2.15: (–)-Ipc2BOMe was prepared in situ according to the following 
procedure: 
To a stirring solution of (+)-α-pinene (80 ml, 503.5 mmol, 2.4 equiv.) in anhydrous THF 
(8 M, 62.9 ml) at room temperature, BH3.DMS (19.9 ml, 20.98 mmol, 1.0 equiv.) was 
added rapidly. The reaction flask was kept in water bath to hold room temperature. 
Stopped stirring immediately when addition was finished. After the water bath was 
removed, the reaction flask was kept untouched under nitrogen overnight (>12 h). Next 
the reaction flask was cooled at 0 oC for 1 hour. The white crystalline solid was crushed 
with needle and the supernatant liquid was removed using a cannula. The solid was 
further washed with anhydrous pentane three times before it was dried under high 
vacuum for 1 hour. The resulting white crystalline solid of Ipc2BH (~47 g, 164.16 mmol) 
was stirred vigorously in anhydrous Et2O (1 M, 164 ml) at 0 oC for 1 hour to form a 
suspension. Then anhydrous methanol (7.97 ml, 197 mmol, 1.2 equiv., precooled to 0 oC) 
was added dropwise to the suspension at 0 oC using syringe pump over a period of 2 to 3 
hours. The mixture was stirred at 0 oC until a clear homogeneous solution was formed 
indicating the completion of methanolysis. Finally, the solvent and excess methanol were 
removed under high vacuum for 3 hours to provide (–)-Ipc2BOMe (48 g, 72.3% for two 
steps) as colorless oil (white crystalline solid upon storage in -80 oC refrigerator). 
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  To a solution of 3-methoxy-1-propene (14.92 ml, 159 mmol, 1.41 equiv.) in anhydrous 
THF (2.5 M, 63.58 ml) was added sec-butyllithium (106.3 ml, 1.36 M in cyclohexane, 
144.51 mmol, 1.29 equiv.) dropwise at -78 oC. The reaction mixture became orange red. 
After 20 minutes, (–)-Ipc2BOMe (48 g, 151.74 mmol, 1.35 equiv.) dissolved in 
anhydrous THF (1 M, 151 ml) was added dropwise at -78 oC. The reaction mixture 
decayed to colorless or pale yellow upon completion of the addition. After 1 hour, boron 
trifluoride etherate (24.91 ml, 201.8 mmol, 1.8 equiv.) was added dropwise at -78 oC 
followed the addition of aldehyde 2.14 (19.6 g, 112.4 mmol, 1.0 equiv.) in anhydrous 
THF (1 M, 112 ml). The mixture was stirred at -78 oC for 12 hours before the cooling 
bath was removed. Then the mixture was warmed up to room temperature before it was 
quenched with ethanolamine (10 ml, 167 mmol, 1.49 equiv.) at 0 oC. The reaction 
mixture became cloudy upon the addition. After stirring 2 hours at 0 oC, the reaction 
mixture was stirred at room temperature for 24 hours. Saturated aqueous NH4Cl was 
added. The organic layer was separated, and the aqueous layer was extracted with Et2O. 
The combined organic layers were washed with brine, dried over MgSO4, and filtered. 
The filtrate was concentrated in vacuo to provide the crude product as light-yellow oil. 
This oil was then purified with silica gel flash column chromatography (19:1 to 9:1 
hexane/EtOAc) to afford the title compound (22.1 g, 80%, 95% dr, 93% ee) as colorless 
oil. [a]D 22 = – 12.6 (c 1.0, CH2Cl2); IR (film) 3476.06 2930.31 2857.02 1471.42 1254.47 
1115.62 926.628 836.955 777.172 cm-1; 1H NMR (500 MHz, Chloroform-d) δ 5.79 – 
5.71 (m, 1H), 5.37 – 5.30 (m, 2H), 3.72 – 3.59 (m, 4H), 3.35 (s, 3H), 2.60 (d, J = 4.0 Hz, 
1H), 0.92 (s, 9H), 0.09 (d, J = 2.9 Hz, 6H); 13C NMR (126 MHz, Chloroform-d) δ 
135.05, 119.39, 83.12, 74.05, 63.53, 56.76, 26.01, 18.42, -5.27, -5.29; HRMS (ESI) m/z 
247.1735 [(M+H)+; calcd for C12H27O3Si: 247.1729]. 
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The absolute configuration at C-4 was determined by Mosher ester analysis: 
 
 
(S)-MTPA Ester of (-)-2.15: To a solution of (-)-2.15 (8.5 mg, 0.034 mmol, 1.0 equiv.) 
in 0.4 ml DCM, DMAP (16.6 mg, 0.136 mmol, 4.0 equiv.) was added at room 
temperature followed by addition of (R)-MTPA-Cl (12.9 μl, 0.069 mmol, 2.0 equiv.). 
After stirring for 0.5 hour at room temperature, the reaction was quenched with saturated 
aqueous NH4Cl. The organic layer was separated, and the aqueous layer was extracted 
with DCM. The combined organic layers were washed with brine, dried over MgSO4, and 
filtered. The filtrate was concentrated in vacuo to provide the crude product as orange red 
oil. This oil was then purified with silica gel flash column chromatography (19:1 
hexane/EtOAc) to afford the title compound (15.48 mg, 97%) as light-yellow oil. 1H 
NMR (500 MHz, Chloroform-d) δ 7.70 – 7.60 (m, 2H), 7.41 (dd, J = 5.2, 2.0 Hz, 3H), 
5.60 (ddd, J = 16.9, 10.6, 7.5 Hz, 1H), 5.35 – 5.17 (m, 3H), 3.85 (dd, J = 11.4, 3.3 Hz, 
1H), 3.81 – 3.71 (m, 2H), 3.67 – 3.57 (m, 3H), 3.20 (s, 3H), 0.90 (s, 9H), 0.07 (d, J = 2.7 
Hz, 6H); HRMS (ESI) m/z 463.2132 [(M+H)+; calcd for C22H34F3O5Si: 463.2128].   
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(R)-MTPA Ester of (-)-2.15 was prepared followed the same procedure with (S)-MTPA 
acid chloride. 1H NMR (500 MHz, Chloroform-d) δ 7.71 – 7.62 (m, 2H), 7.41 (dd, J = 
5.0, 2.0 Hz, 3H), 5.71 (ddd, J = 17.5, 10.3, 7.4 Hz, 1H), 5.45 – 5.34 (m, 2H), 5.17 (ddd, J 
= 7.8, 4.9, 3.3 Hz, 1H), 3.90 (t, J = 7.4 Hz, 1H), 3.80 – 3.66 (m, 2H), 3.61 (s, 3H), 3.31 
(s, 3H), 0.86 (s, 9H), -0.01 (d, J = 1.8 Hz, 6H), HRMS (ESI) m/z 485.1960 [(M+Na)+; 
calcd for C22H33F3O5SiNa: 485.1947]. 
The benzoate derivative of the title compound and its enantiomer were made for UV 
detection in chiral SFC. 
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Table 3.1 Determination of enantiomeric excess for (-)-2.15 by chiral SFC 
 
 
Sample tR 1 Area 1(%) tR 2 Area 2(%) 
(±)-2.15 3.807 53.995 4.303 46.005 
(–)-2.15 3.828 96.645 4.370 3.355 
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SFC condition: column: Chiralcel® OJ-H column (5 μm, 4.6 mm Å~ 250 mm); eluent: 
99.8:0.2 supercritical CO2/MeOH; flow rate: 4 mL/min; pressure:12 MPa; time: 10 min. 
 
 
Alkene (-)-2.38: To a solution of alcohol (-)-2.15 (20.9 g, 84.8 mmol, 1.0 equiv.) in 
DCM (0.25 M, 339 ml), DMAP (1.55 g, 12.72mmol, 0.15 equiv.) added at room 
temperature. Then the mixture was cooled to -78 oC followed by addition of DIPEA (44.3 
ml, 254.4 mmol, 3.0 equiv.) and acryloyl chloride (13.7 ml, 169.63 mmol, 2.0 equiv.). 
After stirring for 10 hours, the reaction mixture was quenched with saturated aqueous 
NH4Cl at -78 oC and was warmed up to room temperature. The organic layer was 
separated, and the aqueous layer was extracted with DCM. The combined organic layers 
were washed with brine, dried over MgSO4, and filtered. The filtrate was concentrated in 
vacuo to provide the crude product as orange red oil. This oil was then purified with 
silica gel flash column chromatography (19:1 hexane/EtOAc) to afford the title 
compound (20.4 g, 80%) as light-yellow oil. [a]D 22 = – 13.2 (c 1.0, CH2Cl2); IR (film) 
2930.31 1729.83 1471.42 1405.85 1258.32 1191.79 1096.33 984.482 837.919 55.656 10 
777.172; 1H NMR (500 MHz, Chloroform-d) δ 6.44 (dd, J = 17.3, 1.4 Hz, 1H), 6.18 (dd, 
J = 17.3, 10.4 Hz, 1H), 5.85 (dt, J = 10.4, 1.1 Hz, 1H), 5.72 (ddd, J = 17.5, 10.4, 7.2 Hz, 
1H), 5.38 – 5.28 (m, 2H), 5.04 (q, J = 5.2 Hz, 1H), 3.93 – 3.87 (m, 1H), 3.83 (dd, J = 
10.7, 5.4 Hz, 1H), 3.72 (dd, J = 10.6, 5.9 Hz, 1H), 3.33 (s, 3H), 0.89 (s, 9H), 0.06 (d, J = 
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5.8 Hz, 6H); 13C NMR (126 MHz, Chloroform-d) δ 165.82, 134.30, 131.05, 128.56, 
119.03, 80.74, 75.74, 61.22, 57.31, 25.90, 25.77, 18.31, -5.32, -5.35; HRMS (ESI) m/z 
301.1838 [(M+H)+; calcd for C15H29O4Si: 301.1835]. 
 
 
Alkene (+)-2.39 was isolated as byproduct from above reaction (~10%). [a]D 22 = + 22.2 
(c 1.0, CH2Cl2); IR (film) 2930.31 2857.02 1730.8 1406.82 1255.43 1192.76 1137.8 
983.518 835.99 808.992 cm-1; 1H NMR (500 MHz, Chloroform-d) δ 6.41 (dt, J = 17.3, 
1.6 Hz, 1H), 6.13 (ddd, J = 17.4, 10.5, 1.4 Hz, 1H), 5.83 (dt, J = 10.4, 1.6 Hz, 1H), 5.79 – 
5.67 (m, 1H), 5.33 – 5.26 (m, 2H), 4.29 (dt, J = 11.2, 2.2 Hz, 1H), 4.05 (ddd, J = 11.2, 
7.4, 1.4 Hz, 1H), 3.96 (tt, J = 5.6, 4.3, 1.9 Hz, 1H), 3.58 (t, J = 6.4 Hz, 1H), 3.30 (s, 3H), 
0.89 (s, 9H), 0.08 (d, J = 9.0 Hz, 6H); 13C NMR (126 MHz, Chloroform-d) δ 166.16, 
134.50, 130.83, 128.53, 118.88, 84.42, 72.56, 66.26, 56.98, 25.90, 18.29, -4.49, -4.60. 
HRMS (ESI) m/z 301.1838 [(M+H)+; calcd for C15H29O4Si: 301.1835]. 
 
 
Lactone (-)-2.17: Alkene (-)-2.38 (12 g, 39.93 mmol, 1.0 equiv.) and Hoveyda-Grubbs 
catalyst 2nd generation (475.49 mg, 0.7588 mmol, 1.9% equiv.) were added to a 2 L 
O
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round bottom flask. Then it was connected with a vigreux condenser. The system was 
backfilled with argon three times. Freshly distilled toluene (0.053 M, 750 ml) was added 
via cannulation to form a dark green reaction mixture. The flask was then put into a 110 
oC oil bath and heated for 12 hours. The reaction mixture turned to dark brown. After 
cooling, the reaction mixture was concentrated in vacuo to provide the crude product as a 
black brown oil. This oil was then purified with silica gel flash column chromatography 
(9:1 to 4:1 hexane/EtOAc) to afford the title compound (9 g, 82%) as brown solid. [a]D 22 
= – 162.7 (c 1.0, CH2Cl2); IR (film) 2929.34 2856.06 1725.01 1462.74 1383.68 1253.5 
1098.26 1073.19 1006.66 836.955 cm-1; 1H NMR (500 MHz, Chloroform-d) δ 7.08 (dd, J 
= 9.8, 5.4 Hz, 1H), 6.19 (d, J = 9.7 Hz, 1H), 4.41 (ddd, J = 8.4, 5.5, 2.9 Hz, 1H), 4.01 (dd, 
J = 10.0, 8.3 Hz, 1H), 3.94 (dd, J = 5.4, 3.0 Hz, 1H), 3.87 (dd, J = 10.0, 5.6 Hz, 1H), 3.44 
(s, 3H), 0.91 (s, 9H), 0.10 (s, 6H); 13C NMR (126 MHz, Chloroform-d) δ 162.72, 142.42, 
124.44, 80.02, 67.48, 60.40, 57.48, 25.93, 18.34, -5.31, -5.44; HRMS (ESI) m/z 273.1514 
[(M+H)+; calcd for C13H25O4Si: 273.1522]. 
 
 
Alcohol 2.48: To a solution of lactone (-)-2.17 (22 g, 80.76 mmol, 1.0 equiv.) in DCM 
(0.22 M, 360 ml), DIBAL (74 ml, 1.2M in toluene, 88.83 mmol, 1.1 equiv.) was added 
dropwise at -78 oC. After 1 hour, the reaction mixture was quenched with MeOH at -78 
oC. Then cooling bath was removed followed by addition of saturated aqueous NaHCO3 
OH
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and saturated aqueous Rochelle’s ester. Stirred vigorously overnight. The organic layer 
was separated, and the aqueous layer was extracted with DCM. The combined organic 
layers were washed with brine, dried over MgSO4, and filtered. The filtrate was 
concentrated in vacuo to provide the crude product which was used for the next step 
without further purification. 
    The crude hemilactal from last step was dissolved in anhydrous EtOH (0.176 M, 460 
ml) and PPTS (4.059 g, 0.2 equiv.) was added in one portion. The reaction was stirred at 
room temperature for 3 hours before quenched with NaHCO3 solid (~5 g added 
portionwise) at 0 oC. After stirred for 0.5 hour at room temperature, the mixture was 
filtered and concentrated in vacuo to provide the crude product which was used for the 
next step without further purification. 
A solution of the crude lactal 2.18 from last step in anhydrous THF (0.22 M, 360 ml) 
was treated with TBAF (88.84 ml, 1 M in THF, 88.84 mmol, 1.1 equiv.) dropwise at 
room temperature. After 2 hours, the reaction mixture was quenched with saturated 
aqueous NH4Cl. The organic layer was separated, and the aqueous layer was extracted 
with EtOAc. The combined organic layers were washed with brine, dried over MgSO4, 
and filtered. The filtrate was concentrated in vacuo to provide the crude product as brown 
oil. This oil was then purified with silica gel flash column chromatography (1:1 to 3:2 
hexane/EtOAc) to afford the title compound (12.46 g, diastereomeric mixture, 82% for 
three steps) as brown solid. IR (film) 3445.21 2975.62 2890.77 1388.5 1322.93 1188.9 
1103.08 1053.91 1012.45 743.424 cm-1; 1H NMR (500 MHz, Chloroform-d) δ 6.15 
(dddd, J = 55.2, 10.4, 4.4, 1.3 Hz, 1H), 6.07 – 5.87 (m, 1H), 5.07 (dd, J = 26.8, 2.4 Hz, 
1H), 4.14 – 3.80 (m, 4H), 3.65 – 3.52 (m, 2H), 3.41 (d, J = 2.6 Hz, 3H), 1.29 – 1.18 (m, 
 90 
3H); 13C NMR (126 MHz, Chloroform-d) δ 130.71, 130.45, 127.79, 126.04, 96.37, 94.04, 
74.10, 71.56, 70.26, 70.23, 64.20, 63.87, 62.96, 62.36, 56.70, 56.57, 15.40, 15.36; HRMS 
(ESI) m/z 211.0927 [(M+Na)+; calcd for C9H16O4Na: 211.0946]. 
 
 
Aldehyde 2.19: A solution of alcohol 2.48 (4.05 g, 21.52 mmol, 1.0 equiv.) in DCM/H2O 
(0.09 M, 240 ml, 1:1/v:v) was treated with TEMPO (3.36 g, 21.52 mmol, 1.0 equiv.) and 
BAIB (7.62 g, 23.67 mmol, 1.1 equiv.) portionwise at room temperature. After stirring 
vigorously for 2 hours, the reaction was cooled to 0 oC and was quenched with solid 
NaHCO3 (~4.4 g) and solid Na2S2O3 (~400 mg) carefully. Stirred vigorously for 1 hour. 
The organic layer was separated, and the aqueous layer was extracted with EtOAc. The 
combined organic layers were washed with brine, dried over MgSO4, and filtered. The 
filtrate was concentrated in vacuo to provide the crude product as orange oil. This oil was 
then purified with silica gel flash column chromatography (3:7 hexane/EtOAc) to afford 
the title compound (2.77 g, 69%) as yellow solid. IR (film) 2976.59 97.422 2 2896.56 
1739.48 1321.96 1188.9 1111.76 1051.98 1014.37 892.88 cm-1; 1H NMR (500 MHz, 
Chloroform-d) δ 9.81 – 9.66 (m, 1H), 6.26 – 6.12 (m, 1H), 6.11 – 5.90 (m, 1H), 5.24 – 
5.13 (m, 1H), 4.47 (d, J = 3.1 Hz, 1H), 4.12 – 3.90 (m, 2H), 3.91 – 3.79 (m, 1H), 3.68 – 
3.56 (m, 1H), 3.46 – 3.32 (m, 4H), 1.23 (tdd, J = 7.2, 5.1, 2.1 Hz, 3H); 13C NMR (126 
MHz, Chloroform-d) δ 200.28, 131.59, 130.36, 127.04, 125.27, 96.67, 94.07, 78.52, 
O
O
OMe
OEt
 91 
75.59, 70.89, 69.56, 64.40, 64.19, 56.88, 15.32, 15.27; HRMS (ESI) m/z 209.0799 
[(M+Na)+; calcd for C9H14O4Na: 209.0790]. 
 
 
Phosphonate 2.22: To P(OEt)3 (2.94 g, 17.64 mmol, 1.0 equiv.) in two-neck flask heated 
to 120 oC, (E)-tert-butyl-4-bromobut-2-enoate was added dropwise via a syringe. The 
reaction was stirred at 130 oC for 2 hours before cooling to room temperature. The crude 
was then purified with silica gel flash column chromatography (EtOAc) to afford the title 
compound (4.13 g, 84%) as solid. IR (film) 2980.45 30.072 2 1713.44 1653.66 1367.28 
1328.71 1256.88 1165.76 1026.91 965.68 845.151 cm-1; 1H NMR (500 MHz, 
Chloroform-d) δ 6.78 (dq, J = 15.4, 7.7 Hz, 1H), 5.90 (dd, J = 15.6, 5.1 Hz, 1H), 4.13 (m, 
4H), 2.73 (dd, J = 22.7, 7.9, 1.4 Hz, 2H), 1.49 (s, 9H), 1.34 (t, J = 7.0 Hz, 6H); 13C NMR 
(126 MHz, Chloroform-d) δ 165.03, 136.19, 136.10, 127.82, 127.71, 80.67, 62.36, 62.31, 
31.11, 30.00, 28.22, 16.51. 
 
 
Ester 2.20: To aldehyde 2.19 (590 mg, 3.17 mmol, 1.0 equiv.) in THF (32 ml, 0.1 M) at 
room temperature, phosphonate side chain 2.22 (1.33 g, 4.79 mmol, 1.5 equiv.) and pre-
activated molecular sieves (6.1 g, 4 Å beads, flame-dried) were added followed by 
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addition of LiOH.H2O (200 mg, 4.79 mmol, 1.5 equiv.) in one portion. The mixture was 
then heated at 70 oC with vigorous stirring. The color of the reaction mixture turned to 
yellow then orange and finally dark red. After 0.5 hour, the mixture was filtered via a pad 
of Celite and the filtrate was concentrated in vacuo to provide the crude product as 
orange oil. This oil was then purified with silica gel flash column chromatography (4:1 
hexane/EtOAc) to afford the title compound (590 mg, 60%) as yellow oil. IR (film) 
2976.59 81.6322 2 1706.69 1648.84 1618.95 1367.28 1278.57 1240 1136.83 1099.23 
1043.3 cm-1; 1H NMR (500 MHz, Chloroform-d) δ 7.23 (dd, J = 15.3, 11.0 Hz, 1H), 6.50 
(dd, J = 15.4, 11.1 Hz, 1H), 6.27 – 6.13 (m, 2H), 6.01 (dd, J = 10.1, 3.0 Hz, 1H), 5.83 (d, 
J = 15.2 Hz, 1H), 5.09 (d, J = 2.9 Hz, 1H), 4.66 – 4.57 (m, 1H), 3.85 – 3.75 (m, 1H), 3.60 
– 3.50 (m, 2H), 3.33 (s, 3H), 1.47 (s, 9H), 1.20 (t, J = 7.1 Hz, 3H); 13C NMR (126 MHz, 
Chloroform-d) δ 166.35, 142.96, 138.06, 130.04, 128.92, 126.67, 123.72, 94.23, 94.18, 
80.31, 70.95, 70.93, 70.42, 64.00, 56.74, 28.27, 15.42. 
 
 
Lactone (–)-2.12: To ester 2.20 (510 mg, 1.64 mmol, 1.0 equiv.) in DCM (17 ml, 0.1 M) 
at room temperature, pre-activated molecular sieves (1.5 g, 4 Å powder, flame-dried) was 
added. Then the mixture was cooled to -20 oC, m-CPBA (340 mg, 1.97 mmol, 1.2 equiv., 
purified via literature procedure2) was added in one portion followed by dropwise 
addition of BF3.Et2O. The reaction was stirred at the same temperature for 1 hour before 
it was quenched with saturated aqueous NaHCO3 and saturated aqueous Na2S2O3 at -20 
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oC. The organic layer was separated and the aqueous layer was extracted with EtOAc. 
The combined organic layers were washed with brine, dried over MgSO4, and filtered. 
The filtrate was concentrated in vacuo to provide the crude product as yellow oil. This oil 
was then purified with silica gel flash column chromatography (4:1 to 1:1 hexane/EtOAc) 
to afford the title compound (417 mg, 90.5%) as yellow oil. [a]D 22 = – 119.3 (c 0.96, 
CH2Cl2); IR (film) 2976.59 81.6322 2 1706.69 67.4641 3 1648.84 1618.95 1367.28 
1278.57 1240 1136.83 1099.23 1043.3 cm-1; 1H NMR (500 MHz, Chloroform-d) δ 7.21 
(dd, J = 15.4, 11.0 Hz, 1H), 6.95 (dd, J = 9.9, 4.5 Hz, 1H), 6.55 (dd, J = 15.5, 11.1 Hz, 
1H), 6.24 – 6.14 (m, 2H), 5.90 (d, J = 15.3 Hz, 1H), 5.10 – 5.03 (m, 1H), 4.05 (t, J = 4.3 
Hz, 1H), 3.42 (s, 3H), 1.50 (s, 9H); 13C NMR (126 MHz, Chloroform-d) δ 166.04, 
162.33, 143.00, 141.70, 133.22, 131.63, 125.54, 123.40, 80.73, 79.03, 71.08, 71.03, 
57.42, 28.27; HRMS (ESI) m/z 303.1200 [(M+Na)+; calcd for C15H20O5Na: 303.1208]. 
 
 
Acid (-)-2.21: A solution of lactone (-)-2.21 (608 mg, 2.17 mmol, 1.0 equiv.) in DCM 
(0.29 M, 7.5 ml) was treated with TFA (2.5 ml) dropwise at 0 oC. The reaction mixture 
turned to brown. The mixture was stirred for 4 hours at the same temperature before 
careful removal of the solvent and excess reagent under high vacuum at 0 oC. The residue 
was further dried under vacuum for 2 hours to provide the crude product as brown solid 
which was used for the next step without further purification. IR (film) 2923.07 1722.12 
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1620.39 1381.26 1250.13 1101.64 1056.8 1002.8 826.83 cm-1; 1H NMR (500 MHz, 
Chloroform-d) δ 9.48 (s, 1H), 7.42 (dd, J = 15.4, 11.1 Hz, 1H), 6.98 (dd, J = 9.9, 4.4 Hz, 
1H), 6.67 – 6.57 (m, 1H), 6.30 (dd, J = 15.4, 5.4 Hz, 1H), 6.20 (d, J = 9.9 Hz, 1H), 5.99 
(d, J = 15.3 Hz, 1H), 5.11 (t, J = 4.9 Hz, 1H), 4.09 (t, J = 4.2 Hz, 1H), 3.43 (s, 3H); 13C 
NMR (126 MHz, Chloroform-d) δ 171.85, 162.50, 145.42, 143.13, 135.42, 131.09, 
123.39, 122.29, 78.86, 70.90, 57.38. 
 
 
Aldehyde (-)-2.3: To a solution of the crude acid (-)-2.21 from last step in DCM (0.2 M, 
10.8 ml) at 0 oC, Ghosez’s reagent chloroenamine (0.86 ml, 6.51 mmol, 3.0 equiv.) was 
added dropwise. The cloudy brown mixture became clear. Then the reaction mixture was 
warmed up to room temperature and stirred for 1 hour at the same temperature. DCM was 
removed under high vacuum at 0 oC. The residue was further dried under vacuum for 2 
hours to provide the crude product as brown oil which was used for the next step without 
further purification. 
To a solution of the crude acid chloride from above in anhydrous THF (0.1 M, 21 ml) 
at -78 oC, LiAl(OtBu)3H (2.37 ml, 1.1 M in THF, 2.6 mmol, 1.2 equiv.) was added 
dropwise. The reaction mixture was stirred for 0.5 hour before it was quenched with 
saturated aqueous NaHCO3 and saturated aqueous Rochelle’s ester at -78 oC. After 
stirring vigorously for 1 hour at room temperature, the organic layer was separated and 
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the aqueous layer was extracted with EtOAc. The combined organic layers were washed 
with brine, dried over MgSO4, and filtered. The filtrate was concentrated in vacuo to 
provide the crude product as yellow oil. This oil was then purified with silica gel flash 
column chromatography (3:2 to 2:3 hexane/EtOAc) to afford the title compound (265 
mg, 59% for two steps) as bright yellow solid. [a]D 22 = – 130.3 (c 0.71, CH2Cl2); IR 
(film) 2928.38 1725.98 1680.66 1647.87 1380.78 1250.61 1101.15 1056.8 990.268 
826.348 cm-1; 1H NMR (500 MHz, Chloroform-d) δ 9.62 (d, J = 7.9 Hz, 1H), 7.15 (dd, J 
= 15.4, 10.9 Hz, 1H), 6.98 (dd, J = 9.9, 4.4 Hz, 1H), 6.72 (ddd, J = 15.6, 10.8, 1.6 Hz, 
1H), 6.38 (dd, J = 15.5, 5.5 Hz, 1H), 6.24 (dd, J = 15.6, 8.0 Hz, 1H), 6.20 (dd, J = 9.9, 
0.8 Hz, 1H), 5.13 (t, J = 5.1 Hz, 1H), 4.12 (t, J = 4.2 Hz, 1H), 3.44 (s, 3H); 13C NMR 
(126 MHz, Chloroform-d) δ 193.54, 161.98, 149.85, 142.92, 136.18, 133.27, 131.29, 
123.49, 78.75, 70.90, 57.32, 29.82; HRMS: a mass spectrometric analysis was not 
possible since only polymer was detected. 
 
 
Alcohol 2.24: To a solution of methyl propargyl ether (4.15 g, 59.2 mmol, 1.05 equiv.) in 
anhydrous THF (1.4 M, 40 ml) at -78 oC, n-butyllithium (34.36 ml, 53.6 mmol, 1.56 M in 
hexane, 1.0 equiv.) was added dropwise. After 1 hour, a solution of propionaldehyde 
(4.07 ml, 53.6 mmol, 1.0 equiv.) in anhydrous THF (1.4 M, 40 ml) was added via cannula 
at the same temperature. The reaction mixture was stirred for 3 hours at -78 oC before it 
was quenched by saturated aqueous NH4Cl. The organic layer was separated, and the 
aqueous layer was extracted with Et2O. The combined organic layers were washed with 
MeO
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brine, dried over MgSO4, and filtered. The filtrate was concentrated in vacuo (25 oC 
water bath) to provide the crude product (5.84 g, 85%) as yellow oil. IR (film) 3399.89 
2934.16 1453.1 1358.6 1187.94 1140.69 1101.15 1037.52 966.162 910.236 cm-1; 1H 
NMR (500 MHz, Chloroform-d) δ 4.39 (tt, J = 6.4, 1.7 Hz, 1H), 4.15 (d, J = 1.7 Hz, 2H), 
3.40 (s, 3H), 1.82 – 1.70 (m, 2H), 1.03 (t, J = 7.4 Hz, 3H); 13C NMR (126 MHz, 
Chloroform-d) δ 87.57, 80.71, 63.83, 60.02, 57.70, 30.95, 9.53; HRMS (ESI) m/z 
128.0833 [M+; calcd for C7H12O2: 128.0837]. 
 
 
Alcohol 2.25: To a solution of propargyl alcohol 2.24 (5.92 g, 46.2 mmol, 1.0 equiv.) in 
methanol (0.58 M, 80 ml), Lindlar Catalyst (592 ml, 10% w/w) was added at room 
temperature. The reaction flask was backfilled with H2 for three times. The reaction was 
carefully monitored via TLC analysis until no starting material left. After about 2 hours, 
the reaction mixture was filtered through Celite. The filtrate was concentrated in vacuo 
(25 oC water bath) and methanol was further removed via a vigreux column. The 
resulting crude (orange oil) was used for the next step without further purification. IR 
(film) 3398.92 2963.09 2929.34 2877.27 1455.99 1190.83 1096.33 1007.62 961.341 
911.201 cm-1; 1H NMR (500 MHz, Chloroform-d) δ 5.68 (dt, J = 11.7, 6.2 Hz, 1H), 5.61 
(dd, J = 11.3, 8.1 Hz, 1H), 4.33 (q, J = 7.0 Hz, 1H), 4.08 (ddd, J = 12.3, 6.6, 1.4 Hz, 1H), 
3.97 (ddd, J = 12.4, 5.8, 1.2 Hz, 1H), 3.36 (s, 3H), 2.11 (s, 1H), 1.63 (dp, J = 14.4, 7.3 
Hz, 1H), 1.50 (dp, J = 14.4, 7.3 Hz, 1H), 0.92 (t, J = 7.4 Hz, 3H); 13C NMR (126 MHz, 
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Chloroform-d) δ 136.33, 127.64, 69.15, 69.12, 68.38, 58.21, 30.21, 9.70; HRMS (CI) m/z 
113.0968 [(M-OH)+; calcd for C7H13O: 113.0961]. 
 
 
Alkene 2.26: To a solution of alcohol 2.25 crude from last step in anhydrous THF (0.53 
M, 80 ml), NaH (2.15 g, 85 mmol, 95% in mineral oil, 2.0 equiv.) was added portionwise 
at 0 oC. The reaction mixture was stirred for 1 hour at the same temperature. Then MeI 
(5.3 ml, 85 mmol, 2.0 equiv.) was added dropwise at 0 oC. Then the mixture was warmed 
up to room temperature. After 12 hours, the mixture became pale white slurry. The 
reaction was then quenched carefully with saturate aqueous NH4Cl at 0 oC. The organic 
layer was separated and the aqueous layer was extracted with Et2O. The combined 
organic layers were washed with brine, dried over MgSO4, and filtered. The filtrate was 
concentrated in vacuo (25 oC water bath) to provide the crude product as orange oil. This 
oil was then purified with silica gel flash column chromatography (4:1 pentane/Et2O) to 
afford the title compound (5.2 g, 84.8% for two steps) as colorless oil. IR (film) 2962.13 
2927.41 1715.37 1456.96 1375.96 1260.25 1194.69 1094.4 804.171 cm-1; 1H NMR (500 
MHz, Chloroform-d) δ 5.77 (dddd, J = 11.4, 6.9, 5.8, 1.1 Hz, 1H), 5.42 (ddt, J = 10.9, 
9.0, 1.6 Hz, 1H), 4.07 (ddd, J = 12.4, 7.0, 1.5 Hz, 1H), 3.98 (ddd, J = 12.4, 5.8, 1.7 Hz, 
1H), 3.87 – 3.81 (m, 1H), 3.35 (s, 3H), 3.27 (s, 3H), 1.71 – 1.58 (m, 1H), 1.45 (dp, J = 
14.4, 7.3 Hz, 1H), 0.89 (t, J = 7.5 Hz, 3H); 13C NMR (126 MHz, Chloroform-d) δ 133.75, 
129.87, 78.17, 68.46, 58.21, 56.20, 28.43, 9.67; HRMS (ESI) m/z 115.0743 [(M-Et)+; 
calcd for C6H11O2: 115.0759]. 
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Dienyl Ether 2.4: To a solution of alkene 2.26 (2 g, 13.87 mmol, 1.0 equiv.) in 
anhydrous Et2O (0.45 M, 30.8 ml) was added n-butyllithium (8.32 ml, 20.8 mmol, 2.5 M 
in hexane, 1.5 equiv.) at -20 oC. The clear solution became pale yellow suspension as n-
butyllithium was added. The reaction mixture was stirred at -20 oC for 40 minutes before 
it was quenched by water. The organic layer was separated and the aqueous layer was 
extracted with Et2O. The combined organic layers were washed with brine, dried over 
MgSO4, and filtered. The solvent was then removed via a vigreux column to provide a 
light-yellow oil. This oil was then purified quickly with silica gel flash column 
chromatography with pentane to afford the title compound (1.43 g, 92%) as colorless oil. 
(Caution: the product is rather volatile.) IR (film) 3733.51 3445.21 2968.87 1731.76 
1693.19 1456.96 1114.65 975.804 668.214 cm-1; 1H NMR (500 MHz, Chloroform-d) δ 
6.35 (dd, J = 15.5, 11.0 Hz, 1H), 5.82 (d, J = 6.0 Hz, 1H), 5.63 (dt, J = 14.0, 6.5 Hz, 1H), 
5.06 (dd, J = 10.8, 6.1 Hz, 1H), 3.66 (d, J = 0.8 Hz, 3H), 2.11 (p, J = 7.2 Hz, 2H), 1.01 (t, 
J = 7.5 Hz, 3H); 13C NMR (126 MHz, Chloroform-d) δ 145.67, 133.18, 121.77, 107.14, 
60.05, 26.01, 13.83; HRMS (ESI) m/z 112.0880 [M+; calcd for C7H12O: 112.0888]. 
 
 
Iodide 2.30: To a solution of dienyl ether 2.3 (500 mg, 4.46 mmol, 1.0 equiv.) in 
anhydrous THF (0.45 M, 9.9 ml) at room temperature was added potassium tert-butoxide 
solid (750 mg, 6.69 mmol, 1.5 equiv.). The reaction mixture was stirred until all the solid 
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was dissolved to form a yellow suspension. This suspension was then cooled to -78 oC 
followed by the addition of n-butyllithium (5 ml, 7.35 mmol, 1.48 M in hexane, 1.65 
equiv.) dropwise. The reaction mixture turned to orange then red and finally deep dark 
red. After 0.5 hour, the solution of iodide (1.87 g, 7.35 mmol, 1.65 equiv., precooled to-
78 oC) in anhydrous Et2O (0.35 M, 21 ml) was cannulated to above reaction mixture at -
78 oC. The red color decayed to form an orange-red turbid mixture. The reaction mixture 
was stirred for 1 hour before it was quenched with saturated aqueous NaHCO3 and 
saturated aqueous Na2S2O3 at -78 oC. Then the mixture was warmed up to room 
temperature and was stirred vigorously. The organic layer was separated and the aqueous 
layer was extracted with Et2O. The combined organic layers were washed with brine, 
dried over MgSO4, and filtered. The filtrate was concentrated in vacuo (25 oC water bath) 
to provide the crude product as orange yellow oil. This oil was then purified quickly with 
silica gel flash column chromatography (1.5% NEt3 buffered) with pentane to afford the 
title compound (795 mg, 75%) as bright yellow oil. (Caution: the product is sensitive to 
light and oxygen, store under nitrogen with copper wire at low temperature.) IR (film) 
2963.09 34.0646 2 2930.31 39.9214 3 1599.66 1454.55 1343.18 1186.01 1065.48 968.09 
927.593 711.604 cm-1; 1H NMR (500 MHz, Chloroform-d) δ 6.25 (dd, J = 15.5, 10.7 Hz, 
1H), 5.95 (d, J = 10.6 Hz, 1H), 5.63 (dt, J = 15.3, 6.7 Hz, 1H), 3.50 (s, 3H), 2.08 (p, J = 
7.7, 7.2 Hz, 2H), 1.01 (t, J = 7.4 Hz, 4H); 13C NMR (126 MHz, Chloroform-d) δ 135.45, 
127.01, 122.98, 62.04, 25.75, 13.54; HRMS (ESI) m/z 112.0882 [(M-I)+; calcd for 
C7H12O: 112.0888]. 
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Stannane 2.29: To a solution of dienyl ether 2.4 (300 mg, 2.67 mmol, 1.0 equiv.) in 
anhydrous THF (0.45 M, 5.9 ml) at room temperature was added potassium tert-butoxide 
solid (330 mg, 2.94 mmol, 1.1 equiv.). The reaction mixture was stirred until all the solid 
was dissolved to form a yellow suspension. This suspension was then cooled to -78 oC 
followed by the addition of n-butyllithium (1.3 ml, 3.23 mmol, 2.5 M in hexane, 1.21 
equiv.) dropwise. The reaction mixture turned to orange then red and finally deep dark 
red. After 0.5 hour, the precooled (-78 oC) solution of iodide (1 g, 3.23 mmol, 1.21 
equiv.) was cannulated to above reaction mixture at -78 oC. The red color decayed to 
form a golden yellow solution. The reaction mixture was stirred for 20min hour before it 
was warmed up naturally to room temperature. After 0.5 h, the reaction was quenched 
with saturated aqueous NaHCO3. The organic layer was separated and the aqueous layer 
was extracted with Et2O. The combined organic layers were washed with brine, dried 
over MgSO4, and filtered. The filtrate was concentrated in vacuo to provide the crude 
product as yellow oil. This oil was then purified with silica gel flash column 
chromatography (1.5% NEt3 buffered) with pentane to afford the title compound (537 
mg, 50%) as bright yellow oil. IR (film) 2926.45 1568.81 1458.89 1376.93 1298.34 
1195.17 1115.62 971.947 874.078 667.732 cm-1; 1H NMR (500 MHz, Chloroform-d) δ 
6.52 (dd, J = 15.4, 10.4 Hz, 1H), 5.61 (dt, J = 15.5, 6.6 Hz, 1H), 5.28 (d, J = 10.5 Hz, 
1H), 3.63 (s, 3H), 2.16 – 2.08 (m, 2H), 1.59 – 1.50 (m, 6H), 1.36 (h, J = 7.3 Hz, 7H), 1.04 
– 0.98 (m, 9H), 0.92 (t, J = 7.3 Hz, 9H);13C NMR (126 MHz, Chloroform-d) δ 165.59, 
132.71, 122.23, 122.01, 60.18, 29.12, 27.43, 26.02, 13.88, 13.75, 11.24; HRMS (ESI) m/z 
402.1942 [M+; calcd for C19H38OSn: 402.1945]. 
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TMS Ether (+)-2.28: To vinyl iodide 2.30 (31 mg, 0.13 mmol, 2.0 equiv.) in THF (0.7 
ml, 0.18 M) at -78 oC, t-BuLi (0.15 ml, 1.63 M in pentane, 3.7 equiv.) was added 
dropwise. After stirring for 0.5 hour at the same temperature, linchpin aldehyde (–)-2.5 
(22 mg, 0.088 mmol, 1.0 equiv., precooled to -78 oC) in THF (0.6 ml, 0.14 M) was 
cannulated to the above mixture resulting bright yellow mixture. After stirring for 0.5 
hour at -78 oC, the reaction was quenched with saturated aqueous NaHCO3 solution 
followed by warming up to room temperature. The organic layer was separated and the 
aqueous layer was extracted with Et2O. The combined organic layers were washed with 
brine, dried over MgSO4, and filtered. The filtrate was concentrated in vacuo to provide 
the crude product as yellow oil. This oil was then purified with silica gel flash column 
chromatography (19:1 hexane/EtOAc) to afford the title compound (270 mg, 89%) as 
light-yellow oil. [a]D 22 = + 5.5 (c 1.0, CH2Cl2); IR (film) 3446.17 2929.34 1662.34 
1457.92 1250.61 1103.08 1032.69 972.912 889.023 840.812 cm-1; 1H NMR (500 MHz, 
Chloroform-d) δ 6.35 (dd, J = 14.6, 11.7 Hz, 1H), 5.67 (dt, J = 15.0, 6.6 Hz, 1H), 5.60 (d, 
J = 10.9 Hz, 1H), 4.55 (d, J = 4.6 Hz, 1H), 3.97 (d, J = 7.6 Hz, 1H), 3.71 (s, 3H), 2.84 
(ddt, J = 24.5, 14.0, 7.6 Hz, 4H), 2.20 – 2.06 (m, 4H), 1.89 (td, J = 6.5, 5.9, 3.4 Hz, 1H), 
1.08 – 1.00 (m, 6H), 0.16 (s, 9H); 13C NMR (126 MHz, Chloroform-d) δ 155.09, 134.51, 
122.68, 113.36, 72.26, 60.05, 51.71, 41.04, 30.59, 30.27, 26.37, 26.09, 13.75, 11.69, 
0.39; HRMS (ESI) m/z 383.1511 [(M+Na)+; calcd for C17H32O2S2SiNa: 383.1510]. 
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Alcohol (+)-2.27: To vinyl iodide 2.30 (400 mg, 1.68 mmol, 2.0 equiv.) in Et2O (11.2 ml, 
0.15 M) at -78 oC, t-BuLi (1.95 ml, 1.59 M in pentane, 3.7 equiv.) was added dropwise. 
After stirring for 0.5 hour at the same temperature, linchpin aldehyde (–)-2.5 (209 mg, 
0.84 mmol, 1.0 equiv.), precooled to -78 oC) in Et2O (7 ml, 0.12 M) was cannulated to the 
above mixture resulting bright yellow mixture. After stirring for 0.5 hour at -78 oC, the 
reaction was quenched with saturated aqueous NaHCO3 solution followed by warming up 
to room temperature. The organic layer was separated and the aqueous layer was 
extracted with Et2O. The combined organic layers were washed with brine, dried over 
MgSO4, and filtered. The filtrate was concentrated in vacuo to provide the crude product 
as yellow oil. This oil was then purified with silica gel flash column chromatography 
(19:1 hexane/EtOAc) to afford the title compound (24 mg, 75%) as light-yellow oil. [a]D 
22 = + 46.8 (c 1.0, CH2Cl2); IR (film) 3468.35 2959.23 1661.37 1456.96 1245.79 1128.15 
1093.44 1027.87 972.912 842.74 cm-1; 1H NMR (500 MHz, Chloroform-d) δ 6.38 (dd, J 
= 15.4, 11.1 Hz, 1H), 5.77 – 5.70 (m, 2H), 4.97 (d, J = 5.0 Hz, 1H), 3.73 (s, 3H), 3.11 
(ddd, J = 15.0, 12.3, 3.2 Hz, 1H), 2.92 (ddd, J = 14.5, 11.7, 3.1 Hz, 1H), 2.72 (q, J = 7.2 
Hz, 1H), 2.50 (dq, J = 13.6, 4.4 Hz, 2H), 2.15 (m, 3H), 2.06 (dd, J = 11.8, 5.7 Hz, 1H), 
1.92 (tdd, J = 12.8, 8.7, 4.0 Hz, 1H), 1.15 (d, J = 7.2 Hz, 3H), 1.05 (t, J = 7.4 Hz, 3H), 
0.30 (s, 9H); 13C NMR (126 MHz, Chloroform-d) δ 157.05, 134.88, 122.43, 111.57, 
69.78, 59.82, 43.15, 42.83, 26.10, 24.40, 24.28, 24.12, 13.76, 10.93, -0.62; HRMS (ESI) 
m/z 383.1503 [(M+Na)+; calcd for C17H32O2S2SiNa: 383.1510]. 
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The absolute configuration of C-3 was determined by Mosher ester analysis: 
 
 
(S)-MTPA Ester of (+)-2.27 was prepared followed the procedure of synthesis of (S)-
MTPA Ester of (-)-2.15. 1H NMR (500 MHz, Chloroform-d) δ 7.72 – 7.54 (m, 2H), 7.45 
– 7.36 (m, 3H), 6.30 (dd, J = 28.0, 15.4 Hz, 1H), 5.62 (dt, J = 14.7, 6.5 Hz, 1H), 5.47 (d, 
J = 10.5 Hz, 1H), 3.79 (s, 3H), 3.59 (s, 3H), 3.01 – 2.92 (m, 1H), 2.85 (t, J = 12.4 Hz, 
1H), 2.75 (q, J = 6.9 Hz, 1H), 2.64 (q, J = 6.9 Hz, 1H), 2.56 – 2.47 (m, 1H), 2.45 – 2.39 
(m, 1H), 2.13 (dt, J = 16.3, 7.6 Hz, 2H), 1.98 (d, J = 13.6 Hz, 1H), 1.89 (t, J = 12.6 Hz, 
1H), 1.31 (d, J = 7.4 Hz, 3H), 1.07 – 1.02 (m, 3H), 0.21 – 0.17 (m, 6H). 
 
 
(R)-MTPA Ester of (+)-2.27 was prepared followed the procedure of synthesis of (R)-
MTPA Ester of (-)-2.15; 1H NMR (500 MHz, Chloroform-d) δ 7.63 – 7.54 (m, 2H), 7.42 
(d, J = 7.7 Hz, 3H), 6.26 (dd, J = 15.5, 10.7 Hz, 1H), 6.09 (s, 1H), 5.50 – 5.41 (m, 1H), 
5.28 (d, J = 10.7 Hz, 1H), 3.76 (s, 3H), 3.56 (s, 3H), 2.98 (t, J = 12.6 Hz, 1H), 2.89 – 2.82 
(m, 1H), 2.71 (q, J = 7.2 Hz, 1H), 2.64 (q, J = 7.1 Hz, 1H), 2.53 – 2.47 (m, 1H), 2.46 (s, 
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1H), 2.11 (p, J = 7.4 Hz, 2H), 2.02 (d, J = 16.2 Hz, 1H), 1.95 – 1.87 (m, 1H), 1.30 (s, 
3H), 1.04 (d, J = 7.5 Hz, 3H), 0.25 (s, 6H). 
 
 
Alkene (+)-2.31: To vinyl iodide 2.30 (30 mg, 0.13 mmol, 1.5 equiv.) in THF (0.8 ml, 
0.18 M) at -78 oC, t-BuLi (0.16 ml, 1.53 M in pentane, 2.85 equiv.) was added dropwise. 
After stirring for 0.5 hour at the same temperature, linchpin aldehyde (–)-2.5 (20.9 mg, 
0.08 mmol, 1.0 equiv., precooled to -78 oC) in THF (0.7 ml, 0.12 M) was cannulated to 
the above mixture resulting light yellow mixture. Allylbromide (0.3 ml, 0.24 mmol, 4.0 
equiv.) was then added dropwise to the reaction mixture before removing the cooling 
bath. After stirring for 0.5 hour at room temperature, the reaction was quenched with 
saturated aqueous NaHCO3 solution. The organic layer was separated and the aqueous 
layer was extracted with Et2O. The combined organic layers were washed with brine, 
dried over MgSO4, and filtered. The filtrate was concentrated in vacuo to provide the 
crude product as yellow oil. This oil was then purified with silica gel flash column 
chromatography (19:1 hexane/EtOAc) to afford the title compound (28 mg, 83%) as 
light-yellow oil. [a]D 22 = + 33.9 (c 1.0, CH2Cl2); IR (film) 2959.23 1662.34 1423.21 
1250.61 1101.15 1029.8 972.912 908.308 869.739 838.883 cm-1; 1H NMR (500 MHz, 
Chloroform-d) δ 6.38 – 6.29 (m, 1H), 6.07 (ddt, J = 17.2, 10.5, 7.1 Hz, 1H), 5.68 (dt, J = 
24.8, 8.8 Hz, 2H), 5.16 – 5.05 (m, 3H), 3.69 (s, 3H), 2.99 (ddd, J = 14.1, 10.7, 3.0 Hz, 
1H), 2.89 (ddd, J = 14.3, 10.6, 3.3 Hz, 1H), 2.69 (dd, J = 15.3, 7.2 Hz, 3H), 2.55 (dd, J = 
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15.5, 6.9 Hz, 1H), 2.42 (q, J = 7.1 Hz, 1H), 2.14 (p, J = 7.2 Hz, 2H), 2.02 – 1.93 (m, 1H), 
1.87 (tq, J = 10.1, 3.3 Hz, 1H), 1.04 (t, J = 7.3 Hz, 6H), 0.18 (s, 6H); 13C NMR (126 
MHz, Chloroform-d) δ 157.23, 134.44, 134.30, 122.34, 117.54, 113.11, 70.03, 59.51, 
58.00, 40.97, 40.05, 26.08, 26.00, 25.44, 24.79, 13.73, 7.85, 1.38, 1.01; HRMS (ESI) m/z 
401.2010 [(M+H)+; calcd for C20H37O2S2Si: 401.2009]. 
 
  
Alcohol (+)-2.2: To vinyl iodide 2.30 (118 mg, 0.5 mmol, 1.5 equiv.) in THF (2.8 ml, 
0.18 M) at -78 oC, t-BuLi (0.6 ml, 1.6 M in pentane, 2.85 equiv.) was added dropwise. 
After stirring for 0.5 hour at the same temperature, linchpin aldehyde (–)-2.5 (82.6 mg, 
0.33 mmol, 1.0 equiv., precooled to -78 oC) in THF (2.2 ml, 0.15 M) was cannulated to 
the above mixture resulting bright yellow mixture. The mixture was stirred for 0.5 hour 
before it was cannulated to aldehyde (–)-2.3 (48.5 mg, 0.23 mmol, 0.7 equiv., precool to -
78 oC) in THF (2.2 ml, 0.1 M). The reaction was stirred at the same temperature for 0.5 
hour before it was quenched with saturated aqueous NaHCO3 solution followed by 
warming up to room temperature. The organic layer was separated and the aqueous layer 
was extracted with EtOAc. The combined organic layers were washed with brine, dried 
over MgSO4, and filtered. The filtrate was concentrated in vacuo to provide the crude 
product as yellow oil. This oil was then purified with silica gel flash column 
chromatography (3:2 hexane/EtOAc) to afford the diastereomeric mixture of 33.4 mg 
(+)-2.2 and 22.24 mg (–)-2.40 (55.6 mg in total, 42%, 52% brsm) as yellow foam. [a]D 22 
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= + 8.0 (c 1.0, CH2Cl2); IR (film) 3428.81 2927.89 1729.83 1683.55 1457.92 1379.34 
1250.13 1099.23 842.258 752.584 cm-1; 1H NMR (500 MHz, Chloroform-d) δ 6.93 (ddd, 
J = 10.0, 4.5, 1.7 Hz, 1H), 6.51 (p, J = 10.6 Hz, 2H), 6.32 (t, J = 12.8 Hz, 2H), 6.16 (dd, J 
= 9.8, 1.7 Hz, 1H), 5.92 (dd, J = 13.9, 7.2 Hz, 1H), 5.70 (dt, J = 14.3, 6.8 Hz, 1H), 5.61 
(d, J = 10.8 Hz, 1H), 5.08 (s, 1H), 4.99 (t, J = 5.6 Hz, 1H), 4.49 (d, J = 5.9 Hz, 1H), 4.16 
(s, 1H), 4.02 (d, J = 4.8 Hz, 1H), 3.69 (s, 3H), 3.43 (s, 3H), 2.79 (dd, J = 13.7, 6.8 Hz, 
4H), 2.43 (d, J = 7.5 Hz, 1H), 2.16 (p, J = 7.2 Hz, 2H), 1.97 (d, J = 6.0 Hz, 2H), 1.18 (dd, 
J = 7.1, 1.7 Hz, 3H), 1.05 (td, J = 7.4, 1.8 Hz, 3H), 0.22 (d, J = 1.8 Hz, 9H); 13C NMR 
(126 MHz, Chloroform-d) δ 162.81, 155.97, 143.12, 135.06, 134.79, 134.12, 131.48, 
125.43, 123.40, 122.08, 113.88, 80.13, 73.47, 71.50, 71.33, 63.07, 60.00, 57.41, 42.88, 
29.83, 26.22, 26.09, 25.49, 24.93, 13.71, 8.36, 1.21, 0.88; HRMS (ESI) m/z 591.2246 
[(M+Na)+; calcd for C28H44O6S2SiNa: 591.2251]. 
The absolute configuration at C-10 was determined by Mosher ester analysis: 
 
 
(S)-MTPA Ester of (+)-2.2 was prepared followed the procedure of synthesis of (S)-
MTPA Ester of (-)-2.15. The product decomposed during the purification therefore the 
crude NMR was used. 1H NMR (500 MHz, Chloroform-d) δ 7.61 (t, J = 4.6 Hz, 2H), 
7.47 – 7.35 (m, 3H), 6.97 (dd, J = 10.0, 4.4 Hz, 1H), 6.53 (dd, J = 15.0, 10.5 Hz, 1H), 
6.44 (dd, J = 15.0, 10.7 Hz, 1H), 6.30 (dd, J = 15.3, 11.1 Hz, 1H), 6.20 – 6.04 (m, 3H), 
OOMe
O
O
OMe
Me
Me
OTMSS S
(S)-MTPA
 107 
5.65 (dt, J = 14.6, 6.6 Hz, 1H), 5.59 (d, J = 11.0 Hz, 1H), 5.05 (s, 1H), 4.99 (d, J = 5.3 
Hz, 1H), 4.03 (t, J = 4.2 Hz, 1H), 3.63 (d, J = 12.4 Hz, 6H), 3.44 (s, 3H), 2.56 (d, J = 14.2 
Hz, 1H), 2.16 – 2.04 (m, 4H), 1.91 (d, J = 7.4 Hz, 1H), 1.77 (s, 1H), 1.68 (d, J = 15.3 Hz, 
2H), 1.02 (t, J = 7.5 Hz, 3H), 0.95 (d, J = 7.0 Hz, 3H), 0.19 (s, 9H). 
 
 
(R)-MTPA Ester of (+)-2.2 was prepared followed the procedure of synthesis of (R)-
MTPA Ester of (-)-2.15. The product decomposed during the purification therefore the 
crude NMR was used. 1H NMR (500 MHz, Chloroform-d) δ 7.62 – 7.52 (m, 2H), 7.41 
(dt, J = 19.6, 4.4 Hz, 3H), 6.96 (dd, J = 9.9, 4.4 Hz, 1H), 6.38 (dd, J = 15.3, 10.3 Hz, 1H), 
6.30 (dd, J = 15.5, 11.1 Hz, 1H), 6.17 (d, J = 10.0 Hz, 3H), 6.07 (dd, J = 15.1, 7.1 Hz, 
1H), 5.80 (dd, J = 15.4, 6.5 Hz, 1H), 5.66 (dt, J = 14.5, 6.5 Hz, 1H), 5.60 (d, J = 10.8 Hz, 
1H), 5.05 (s, 1H), 4.97 (d, J = 5.4 Hz, 1H), 4.02 (t, J = 4.2 Hz, 1H), 3.69 (s, 3H), 3.61 (s, 
3H), 3.44 (s, 3H), 2.91 (t, J = 12.4 Hz, 2H), 2.69 – 2.51 (m, 2H), 2.17 – 2.08 (m, 3H), 
1.99 (s, 1H), 1.85 (d, J = 12.3 Hz, 1H), 1.02 (d, J = 7.5 Hz, 3H), 0.96 (d, J = 7.0 Hz, 3H), 
0.22 (s, 9H). 
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Alcohol (–)-2.40: The title compound was isolated as one of the diastereomers in the key 
union reaction. [a]D 22 = – 14.6 (c 0.74, CH2Cl2); IR (film) 3456.78 2928.86 1729.35 
1380.3 1249.65 1098.26 1053.43 841.294 752.102 cm-1; 1H NMR (500 MHz, 
Chloroform-d) δ 6.96 (dd, J = 9.9, 4.5 Hz, 1H), 6.56 – 6.48 (m, 2H), 6.33 (ddt, J = 14.3, 
10.9, 1.6 Hz, 1H), 6.29 – 6.24 (m, 1H), 6.17 (d, J = 9.9 Hz, 1H), 5.94 – 5.89 (m, 1H), 
5.70 (dt, J = 15.4, 6.6 Hz, 1H), 5.64 (d, J = 11.0 Hz, 1H), 5.13 (s, 1H), 4.97 (dd, J = 7.0, 
3.8 Hz, 1H), 4.60 (d, J = 4.0 Hz, 1H), 4.00 (t, J = 4.2 Hz, 1H), 3.70 (s, 3H), 3.54 (d, J = 
2.9 Hz, 1H), 3.44 (s, 3H), 2.85 (dtd, J = 29.8, 7.2, 6.8, 4.0 Hz, 3H), 2.71 (ddd, J = 14.5, 
7.6, 3.6 Hz, 1H), 2.28 (q, J = 7.2 Hz, 1H), 2.18 – 2.11 (m, 2H), 1.99 (dq, J = 7.6, 3.9 Hz, 
2H), 1.14 (d, J = 7.2 Hz, 3H), 1.04 (t, J = 7.5 Hz, 3H), 0.24 (s, 6H); 13C NMR (126 MHz, 
Chloroform-d) δ 162.97, 155.78, 143.25, 135.04, 134.90, 133.46, 130.44, 125.26, 123.50, 
122.19, 113.66, 80.42, 71.46, 70.04, 62.56, 59.33, 57.61, 42.73, 29.92, 26.33, 26.17, 
25.68, 25.02, 13.78, 9.75, 1.24, 1.08; HRMS (ESI) m/z 591.2246 [(M+Na)+; calcd for 
C28H44O6S2SiNa: 591.2251]. 
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Aldehyde 2.41: The title compound was isolated as a byproduct in the key union 
reaction. IR (film) 3441.35 2931.27 1727.42 1610.75 1532.17 1251.09 1103.08 990.75 
825.384 cm-1; 1H NMR (500 MHz, Chloroform-d) δ 9.67 (d, J = 7.7 Hz, 1H), 7.36 (dd, J 
= 9.4, 6.6 Hz, 1H), 7.33 – 7.26 (m, 1H), 7.19 (dd, J = 15.1, 11.3 Hz, 1H), 6.53 (d, J = 
15.0 Hz, 1H), 6.38 (dd, J = 15.2, 7.7 Hz, 1H), 6.33 (d, J = 9.4 Hz, 1H), 6.27 (d, J = 6.6 
Hz, 1H); 13C NMR (126 MHz, Chloroform-d) δ 193.08, 160.87, 157.73, 148.50, 143.01, 
135.12, 131.91, 130.45, 116.90, 107.96. 
 
 
Methyl Ether (–)-2.37: To alcohol (+)-2.2 (10 mg, 0.018 mmol, 1.0 equiv.) was treated 
with pre-activated molecular sieves (300 mg, 4 Å powder, flame-dried), silver oxide (204 
mg, 0.88 mmo, 50 equiv.) and MeI (1.2 ml, 0.015 M) at room temperature. The reaction 
was stirred for overnight before it was filtered via a pad of Celite. The filtrate was 
concentrated in vacuo to provide the crude product as yellow oil. This oil was then 
purified with silica gel flash column chromatography (7:3 hexane/EtOAc) to afford the 
title compound (6.7 mg, 65%) as light-yellow oil. [a]D 22 = – 39.5 (c 0.21, CH2Cl2); IR 
(film) 2925 1729.35 1463.22 1379.82 1248.68 1097.78 1055.84 872.631 840.812 cm-1;1H 
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NMR (500 MHz, Chloroform-d) δ 6.97 (dd, J = 9.9, 4.5 Hz, 1H), 6.46 (dd, J = 15.5, 10.2 
Hz, 1H), 6.36 – 6.25 (m, 2H), 6.18 (d, J = 9.9 Hz, 1H), 5.97 (ddd, J = 31.7, 15.3, 7.7 Hz, 
2H), 5.72 – 5.59 (m, 2H), 5.13 (s, 1H), 4.97 (dd, J = 7.3, 3.9 Hz, 1H), 4.11 (d, J = 8.4 Hz, 
1H), 4.02 (t, J = 4.3 Hz, 1H), 3.69 (s, 3H), 3.45 (s, 3H), 3.32 (s, 3H), 2.72 – 2.64 (m, 1H), 
2.59 (d, J = 11.5 Hz, 2H), 2.11 (hept, J = 7.2 Hz, 4H), 1.94 – 1.85 (m, 2H), 1.03 (t, J = 
7.4 Hz, 3H), 0.97 (d, J = 7.2 Hz, 3H), 0.22 (s, 9H); 13C NMR (126 MHz, Chloroform-d) δ 
162.70, 157.31, 143.15, 134.90, 134.26, 132.95, 132.85, 126.04, 123.53, 122.50, 113.02, 
80.27, 71.25, 69.81, 59.57, 57.37, 56.58, 43.51, 29.83, 27.99, 27.72, 26.08, 25.13, 13.73, 
8.10, 1.23, 0.55; HRMS (ESI) m/z 605.2404 [(M+Na)+; calcd for C29H46O6S2SiNa: 
605.2403]. 
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